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Chapter 1: Psoriasis more than skin deep: Introduction 
1.1 Introduction on psoriasis 
Psoriasis is a common chronic inflammatory disease affecting approximately 2% of the 
population in Europe and the United States and is less prevalent elsewhere.7,8 Several 
different clinical phenotypes of psoriasis exists. They can be observed in the same person, 
either simultaneously or over time. Plaque psoriasis is the most common phenotype. It is 
characterised by sharply demarcated, erythematous plaques covered by silvery white scales, 
that preferentially occur on the scalp, buttocks and extensor sites of the knees and elbows. 
Other phenotypes are guttate, inverse, seborrhoeic, localized and generalized pustular and 
erythrodermic psoriasis. The course of the disease is characterised by flares and remissions 
and psoriasis comes in many different degrees of severity.9 
 
Figure 1 – Plaque psoriasis and predilection places. 
 
 
Figure 2 – Other phenotypes of psoriasis: localized pustular (a), inverse (b) and guttate psoriasis (c). 
 
Disease onset is most frequently observed in the early twenties. It has been proposed that two 
types of psoriasis can be recognized (type I and type II), with type I psoriasis, characterized 
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by onset age ≤ 40 years, being more likely to be familial, severe, and strongly associated with 
HLA-Cw6.10,11 
The evolution of a psoriatic lesion is based on a complex interplay between environmental 
and genetic factors. After disease initiation, a cascade of events leads to activation of dendritic 
cells and the generation of  T cells that emigrate to the skin. Cross-talk between epithelial 
cells and immune cells shapes and maintains the inflammatory milieu  wherein key cytokines 
interferon-γ, and TNF-α play an important role.5 
Population studies clearly indicate that the incidence of psoriasis is greater among first-degree 
and second-degree relatives of patients than among the general population. That a genetic 
component may account for this finding is supported by studies of disease concordance 
among twins that show a risk of psoriasis that is two to three times as high among 
monozygotic twins as among dizygotic twins.12 
Recent genome-wide association studies have started to identify specific genetic components 
of both the immune system and the epidermis that affect disease risk. Genetic risk factors 
such as different alleles of IL12B and IL23R affect pathways mediated by IL-12 and IL-23 
which are crucial for the development of the immune cell subsets that drive the epidermal 
component of this skin disease.13 Other factors including TNFAIP3 and TNIP1 affect 
pathways mediated by NFkB such as immunity and inflammation, cell proliferation and 
apoptosis. These could affect both immune cells and keratinocytes, and thereby contribute to 
alterations in epidermal proliferation.14 By contrast, separate psoriasis genetic risk factors, 
such as deletions of late cornified envelope (LCE3)  genes of the epidermal differentiation 
complex, are likely to have a direct effect on skin barrier formation.15 
For many patients, the symptoms of psoriasis improve in summer and worsen in winter, 
reflecting the well-established notion that the course of the disease is influenced by 
environmental factors. Physical trauma may trigger psoriatic lesions at sites of injury 
(Koebner’s phenomenon). Also, life style factors such as smoking, alcohol use, obesity and 
stress can trigger psoriasis onset or have an influence on course of the disease.16-18 
Several treatment options for psoriasis exist. In basic terms, treatment for generalised 
psoriasis follows a 1-2-3 approach, starting with topical therapies, followed by light therapy 
(UVB/PUVA) and conventional systemic medications (methotrexate, acitretin or 
cyclosporine) or biologics (infliximab, etanercept, adalimumab or ustekinumab). Following 
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factors are considered in the treatment decision process: type, severity and localisation of 
psoriasis; age and medical history of patient; patient preferences and impact on health-related 
quality of life.19 
After this brief introduction about the general aspects of  psoriasis, we look closer at the 
different comorbidities in psoriasis, the impact on health-related quality of life and the 
lifestyle factors which have a negative influence on psoriasis and its comorbidities. 
1.2 Comorbidities in psoriasis 
Epidemiological studies indicate that psoriasis patients have a high risk of developing 
comorbidities. First of all, psoriatic arthritis is observed. This can be a mild but often 
debilitating disease with joint damage. Secondly, people with more severe presentations of 
psoriasis appear to have an increased frequency cardiovascular disease, abdominal obesity, 
dyslipidemia, hypertension and glucose intolerance or diabetes. A large, population based 
study found that life expectancy was about four years shorter in patients with severe psoriasis 
than in healthy controls mainly caused by their increased cardiovascular risk.20 Thirdly, 
psychological and psychiatric comorbidities are common in psoriasis having a high impact on 
quality of life of psoriasis patients. Lastly, other psoriasis-related comorbidities such other 
immune-mediated inflammatory disorders, malignancies, infections, non-alcoholic fatty liver 
disease, obstructive sleep apnea syndrome and chronic obstructive pulmonary disease will be 
discussed in this chapter. 
1.2.1 Psoriasis arthritis 
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis marked by 
stiffness, pain, swelling, and tenderness of the joints, as well as adjacent tendons.21 PsA 
occurs in about 1% up to 39% of patients with psoriasis, depending on the population studied. 
The majority of the patients (approximately 70%) develop psoriasis before articular 
involvement; in contrast arthritis precedes the onset of psoriasis by more than 1 year in 
approximately 15% of cases, and in another 15% the two conditions occur together within a 
12 months period.22-24 PsA usually arises between 7 to 10 years after the onset of psoriasis.25 
The onset age of PsA is in the range of 30–55 years with an equal sex distribution.26 
A strong genetic component for PsA has been suggested by several studies.27 Common 
established susceptibility factors for psoriasis and PsA include an HLA-C risk allele28,29 as 
well as variants in or near IL23R and IL12B13,30, whereas a frequent deletion within the 
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epidermal differentiation complex contributes to skin involvement but not to joint 
involvement.15,31  
PsA is classified according to criteria established by Moll and Wright or the ClASsification 
Criteria for Psoriatic ARthritis (CASPAR). In 1973, Moll and Wright defined PsA in patients 
seronegative for rheumatoid factor with positive history of psoriasis, current skin or nail 
psoriasis and inflammatory joints or axial disease. Based on the predominant clinical feature, 
five subsets were identified including distal interphalangeal arthritis, asymmetrical 
oligoarthritis, symmetrical polyarthritis,  spondylitis and arthritis mutilans.32 More recent, the 
CASPAR criteria for psoriatic arthritis require the presence of established inflammatory 
articular disease with at least 3 points from the following features: current psoriasis, a 
personal history of psoriasis, a family history of psoriasis, past or present dactylitis, juxta-
articular new bone formation, rheumatoid factor negativity, and psoriatic nail dystrophy. 
Current psoriasis was assigned a score of 2, while all other features were assigned a score of 
1.1 (Table 1) Unfortunately, there are no validated serologic tests available to aid in the 
diagnosis of psoriatic arthritis.33 
Table 1: The CASPAR criteria (ClASsification criteria for Psoriatic ARthritis)*1 
To meet the CASPAR criteria, a patient must have inflammatory articular disease (joint, spine, or 
entheseal) with ≥3 points from the following 5 categories: 
1. Evidence of current psoriasis, a personal history of psoriasis, or a family history of psoriasis. 
Current psoriasis** is defined as psoriatic skin or scalp disease present today as judged by a 
rheumatologist or dermatologist. A personal history of psoriasis is defined as a history of psoriasis that 
may be obtained from a patient, family physician, dermatologist, rheumatologist, or other qualified 
health care provider. A family history of psoriasis is defined as a history of psoriasis in a first- or 
second-degree relative according to patient report. 
2. Typical psoriatic nail dystrophy 
including onycholysis, pitting, and hyperkeratosis observed on current physical examination. 
3. A negative test result for the presence of rheumatoid factor  
by any method except latex but preferably by enzyme-linked immunosorbent assay or nephelometry, 
according to the local laboratory reference range. 
4. Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis 
recorded by a rheumatologist. 
5. Radiographic evidence of juxtaarticular new bone formation 
appearing as ill-defined ossification near joint margins (but excluding osteophyte formation) on plain 
radiographs of the hand or foot. 
* The CASPAR criteria have specificity of 98.7% and sensitivity of 91.4%. 
** Current psoriasis is assigned a score of 2; all other features are assigned a score of 1. 
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The gravity of PsA is highly variable and can range from a mild arthritis to debilitating 
polyarticular disease with joint damage and loss of functionality.33 Three clinical patterns 
have been identified: oligoarticular (≤4 involved joints) or polyarticular (≥5 involved joints) 
peripheral disease and axial disease with or without associated peripheral arthritis.34 Also, 
distal interphalangeal arthritis and arthritis mutilans may occur.35 Asymmetric oligoarthritis is 
the most common pattern at onset.36 Axial disease has been approximate between 5% and 
36% of patients.37,38 It is characterized by an irregular involvement of the axial skeleton with 
a preference for the cervical spine.39 Recurrent episodes of enthesitis and dactylitis represent a 
characteristic of PsA.1 Associated with psoriasis and PsA, the nails can be involved in up to 
50% of cases. There is a broad spectrum of nail dystrophies, ranging from the common pitting 
and loosening of the nail plate to the less common discoloration and splinter hemorrhages 
seen in the nail bed.40 The nails and joints are associated with inflammation at points of  
tendon insertion (enthesitis), so it is now valued that both of these sites also share a common 
microanatomical basis.41 
Patients with psoriasis should be screened for the presence of  PsA, because early detection 
and aggressive treatment appear to prevent joint damage. Three large validation studies 
recently identified three patient questionnaires as being highly sensitive and specific tools to 
diagnose PsA.42 These questionnaires are the Toronto psoriasis arthritis screen (ToPAS)43, the 
psoriatic arthritis screening and evaluation (PASE) tool44, and the psoriasis epidemiology 
screening tool (PEST).45 The ToPAS questionnaire has been developed to screen for PsA in 
unselected patients, and the PASE and PEST questionnaires are proposed to identify PsA 
among patients with psoriasis.46 If indicated, these patients should be referred to a 
rheumatologist for affirmation of diagnosis and initiation of treatment.25  
Recently the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) developed treatment recommendations based on a literature review and consensus 
between rheumatologists and dermatologists (Table 2).2 
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Table 2: Treatment guidelines for psoriatic arthritis categorised by disease characteristics and distinct 
organ involvement.2  
GRAPPA treatment guidelines for psoriatic arthritis 
Peripheral 
arthitis 
Skin and nail 
disease Axial disease Dactylitis Enthesitis 
Initiate therapy Initiate therapy Initiate therapy Initiate therapy Initiate therapy 
NSAID 
IA steroids 
DMARD (MTX, 
CsA, 
SSZ, LEF) 
BIOLOGICS 
(anti-TNF) 
Topicals 
PUVA/UVB 
Systemics (MTX, 
CsA) 
Biologics (anti-
TNF, etc) 
NSAID 
PT 
Biologics (anti-
TNF) 
NSAID 
Steroid injection 
Biologics (anti-
TNF) 
NSAID 
PT 
Biologics (anti-
TNF) 
Anti-TNF: anti-tumour necrosis factor; CsA: ciclosporin A; DMARD: disease-modifying anti-
rheumatic drug; IA: intra-articular; LEF: leflunomide; MTX: methotrexate; NSAID: non-steroidal 
anti-inflammatory drug; PT: physiotherapy; PUVA: psoralen–ultraviolet light A; SSZ: sulfasalazine; 
UVB: ultraviolet light B. 
 
1.2.2 Cardiovascular and metabolic disease 
Increasing epidemiological evidence suggests independent associations between psoriasis and 
metabolic and cardiovascular disease. Metabolic syndrome is a cluster of risk factors, which 
include abdominal obesity, dyslipidemia, hypertension and glucose intolerance, and is a 
strong predictor of cardiovascular diseases and diabetes type 2.47 Psoriasis patients have an 
increased prevalence of metabolic syndrome and its individual components compared to 
control patients.48 This association increases with increasing disease severity.49 In Table 3, we 
show an overview of numerous studies that reported associations between psoriasis, metabolic 
syndrome and cardiovascular disease since 2006. 
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Table 3: Overview of studies that reported associations between psoriasis and metabolic disease from 
2006 till 2012. 
Year Author Patients Psoriasis is associated with increased risk of … 
2006 Neimann50 131 560 pso diabetes [OR 1.13],  hypertension [OR 1.03],  
hyperlipemia [OR 1.16] 
    479 317 co obesity [OR 1.27] and smoking [OR 1.31]  
  Sommer51 581 pso             diabetes [OR 2.48], hypertension [OR 3.27], 
hyperlipidemia [OR 2.09] 
    1044 co metabolic syndrome [OR 5.29] 
  Mallbris52 200 pso            elevated total cholesterol, HDL and apolipoproteine A1  
    285 co   
  Gelfand53 130 976 pso       myocardial infarct [OR 1.06/1.43] 
    556 995 co   
2007 Cohen54 340 pso            diabetes [OR 1.5], hypertension [OR 1.3], dyslipidemia 
[OR 1.2] 
    6643 co obesity [OR 1.3], ischemic heart disease [OR 1.4]  
  Shapiro55 46 095 pso       diabetes [OR 1.27] and atherosclerosis [OR 1.28] 
    1 579 037 co   
  Gisondi48 338 pso          metabolic syndrome [OR 1.65]  
    334 co   
  Ludwig56 32 pso         coronary arterial calcification [OR 2.11]  
    32 co   
2008 Cohen57 16 851 pso       diabetes [OR 1.2], hypertension [OR 1.3], obesity [OR 
1.7] 
    48 681 co metabolic syndrome [OR 1.3], cardiovascular disease 
[OR 1.1]  
  Dreiher58 10669 pso         dyslipidemia [OR 1.48]  
    22996 co   
2009 Qureshi59 1813 pso           diabetes  [RR 1.63] and hypertension [RR 1.17] 
    76 248 co   
2010 Schmitt60 3147 pso          diabetes  [OR 1.21], hypertension [OR 1.34] 
    3147 co dyslipidemia [OR 1.29], obesity [OR 1.63 ] 
  Cohen61 12 502 pso       hypertension [OR 1.37] 
    24 285 co   
2011 Love62 71 pso          metabolic syndrome [OR 2.16] 
    2385 co   
  Langan49 4065 pso     metabolic syndrome [OR 1.41]; varying in a dose-
response manner 
    40 650 co  from mild OR [1.22] to severe psoriasis OR [1.98] 
  Armesto63 661 pso         hypertension [OR 1.44] 
    661 co   
2012 Li64 3074 pso         diabetes among individuals younger than 60 years [RR 
1.26] 
    159 621 co   
OR: Odds ratio; RR: Relative risk; pso: psoriasis patients; co: control patients. 
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In contrary with the results of these studies, Wakkee et al found in their cohort study that 
psoriasis is not a clinically relevant risk factor for ischemic heart disease hospitalizations on 
the population level.  The authors warned for confounding factors such as an increased 
healthcare consumption in psoriasis patients compared to controls which may bias the study 
results of the previous studies.65  
Identifying the causality of this association remains a challenge. First of all, other major 
factors that can contribute to this unfavorable cardiovascular risk profile include cigarette 
smoking, alcohol consumption, physical inactivity and psychological stress, all having a 
higher prevalence among patients with psoriasis.66 Secondly, medications commonly used to 
treat psoriasis may have an influence on cardiovascular risk in psoriasis. For instance, the 
incidence of hypertension increases with cumulative cyclosporine dose and prolonged 
therapy. Moreover, Gisondi et al described an association between cyclosporine use and new-
onset diabetes. In addition, acitretin and cyclosporine use are associated with lipid 
abnormalities. Furthermore, Prodanovich et al have shown that methotrexate reduces 
cardiovascular risk in rheumatoid arthritis and psoriasis but more recently, a study from Chen 
et al did not confirm this.67,68  Thirdly, a possible link between psoriasis and metabolic 
diseases may be their pro-inflammatory state. Th-1 and Th-17 inflammatory cytokines are 
elevated in the skin and blood of patients with psoriasis. These inflammatory mediators may 
have pleiotropic effect on insulin signalling, lipid metabolism and adipogenesis.69 Also, 
adipokines like leptin and adiponectin originating from adipose tissue, could play a 
pathogenetic role in the association between psoriasis and metabolic disease. Leptin is 
upregulated and adiponectin downregulated in both psoriasis and obesity.70 Further research 
on this topic will be needed to prove this hypothesis. At last, a genetic basis for the 
association between metabolic comorbidities and psoriasis is suggested. Overlapping of 
susceptibility loci (CDKAL-1) has been demonstrated in psoriasis and diabetes type 2.71  
Physicians treating moderate to severe psoriasis should screen for cardiovascular risk factors. 
A clinical consensus and recommendations for screening are discussed in Kimball et al. Their 
council was based on the recommendations of the American Heart Association to screen for 
cardiovascular risk factors from as early as age 20. By age 40, repeat this at least once every 2 
years and to advise lifestyle modifications such as diet, smoking cessation, moderating 
alcohol intake and exercising 3 times a week for 30 minutes, as first line intervention.25 
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We can conclude that an optimal treatment for psoriasis includes clinical improvement but 
also takes into account cardiovascular risk. In this context, there is evidence that statins given 
for its lipid-lowering effects also induce a clinical improvement in psoriasis due to is 
immunomodulatory and anti-inflammatory effects.72 An important question for the future is 
whether biologics will influence cardiovascular and metabolic comorbidities in psoriasis. 
Until now, there is no clear answer on this subject.73  
1.2.3 Psychiatric and psychological comorbidity 
Psoriasis is associated with a major psychological and psychiatric burden. Decreased quality 
of life74, stigmatization75,76, poor self-esteem, stress77 and sexual dysfunction78 are 
psychological implications of psoriasis. In addition, psoriasis patients are at increased risk for 
the development of depression, anxiety and suicidality.79,80 
Psychological stress including actual experiences of discrimination by others and anticipation 
of the potential for stigmatization can be a long-lasting burden in patients with psoriasis. 
Psoriasis patients partly avoid situations potentially creating a feeling of stigmatization (e.g. 
going swinning).76 
Kleyn et al studied whether the social impact of psoriasis is associated with altered cognitive 
processing of disgust using functional magnetic resonance imaging (fMRI) in psoriasis patient 
(n=13) compared to control patients (n=13). They found significantly reduced response in the 
insula cortex of psoriasis patients compared with controls when observing disgusted faces. 
One possible explanation for this is that psoriasis patients develop a coping mechanism to 
protect them from stressful emotional responses by blocking the processing of disgusted facial 
expressions encountered in others.81  
Besides, psoriasis patients are more prone to depression than the general population.79 
Prevalence estimates of depression in psoriasis range between 10%75 to 62%.82 These wide 
ranges are likely related to different depression scoring methods. Lower educational level, 
younger age and the presence of itch were associated with more reported depressive 
symptoms.82,83  Links between psoriasis and depression are not only psychopathological but 
also biological. A study by Himmerich et al suggested that the activation of the TNF-α 
pathway may contribute to the development of depression.84 Also, the risk of suicidal ideation 
is increased in psoriasis patients. Estimates of suicidal ideation in patients with psoriasis 
ranged from 2.5 to 9.7%.85  
 Chapter 1: Psoriasis more than skin deep: Introduction 
 
20 
 
Richards et al found that perceptions of stigmatisation and depression were the most 
important variables in predicting psoriasis-related disability. It would appear that the impact 
of psoriasis on quality of life is not simply reducible to chronicity, severity or location of 
disease activity.75  
Additional to this, psoriasis is associated with an augmented alcohol intake. A study by Kirby 
et al found that 17% up to 30% of psoriasis patients have difficulties with alcohol. Alcohol 
misuse may increase psoriasis severity and is associated with anxiety and depression in 
patients with psoriasis.86 Poikolainen et al found that alcohol intake increases the mortality 
among patients with psoriasis.87 Furthermore, excessive alcohol intake can have implications 
for the cardiovascular comorbidities88 and treatment in psoriasis.89 
Dermatologist are well placed to identify alcohol misuse early in psoriasis patients. McAleer 
et al recommends the Alcohol Use Disorders Identification Test (AUDIT) questionnaire to 
identify alcohol misuse in patients with moderate to severe psoriasis.90 If identified, referral 
for appropriate intervention to prevent potential complications from alcohol misuse is 
recommended.  
Management of the psoriasis patient includes treatment of somatic manifestations but also 
tackle his or her psychological problems and psychiatric comorbidities. Therefore, 
multidisciplinary approach, including family physician, dermatologist, psychiatrist and 
psychologist next to psychosocial interventions are essential. In this context, Fortune et al 
described a cognitive-behavioural symptom management programme delivered in group 
format that improved the clinical severity of psoriasis and psychological disability.91  
1.2.4 Other comorbidities 
Immune-mediated inflammatory disorders  (IMID) 
Psoriasis is considered as an IMID.  Associations with other IMIDs are described at higher 
risk: Crohn’s disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, psoriatic 
arthritis, atopic dermatitis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes 
and celiac disease.92 This is supported by genetic data showing shared genes (Table 4) and 
immunologic data demonstrate common inflammatory mediators (e.g. TNF-α, IL-17, IL-23) 
thereby explaining the related efficacy of biologics.93 
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Table 4 : Genes shared by immune-mediated inflammatory disorders (IMIDs)  
Gene Chromo
-some 
PsO PsA CD UC MS AD RA SLE AS T1D CeD 
IL12B 5q x x x  x x      
IL23R 1p x x x x     X  X 
CDKAL1 6p x  x         
PTPN22 18p x x     x x  x  
IL2/IL21 4q x x x x x  x x  x x 
PsO, psoriasis; PsA, psoriatic arthritis; CD, crohn’s disease,  UC, ulcerative colitis; MS, multiple 
sclerosis; AD, atopic dermatitis; RA, rheumatoid arthritis;  SLE, systemic lupus erythematosus; AS, 
ankylosing spondylitis; T1D, type 1 diabetes; CeD, celiac disease. x, documented disease 
association.5,6 
 
Patients with one or more IMIDs carry a higher chronic disease burden which implies a 
greater healthcare utilization.92 Further research on the common pathogenesis of these IMIDs 
may have diagnostic and therapeutic implications.  
Malignancies 
Various studies have suggested that psoriasis is associated with malignancies such as skin 
cancer, lymphoproliferative disorders94  or solid carcinoma.95  
The increased risk of non-melanoma skin cancer in psoriasis, squamous cell carcinoma, and to 
a lesser extent basal cell carcinoma, has been reported in several studies.94,95 Also, melanoma 
are more prevalent in psoriasis patients.96 Anti-psoriatic treatments such as long-term psoralen 
and ultraviolet A and cyclosporine contribute to this increased risk.96-99  
Besides, psoriasis is associated with an increased risk of lymphoma, especially cutaneous T-
cell lymphoma. This association can be related to the chronic lymphoproliferative nature of 
psoriasis or may be caused by anti-psoriatic treatments such as cyclosporine and 
methotrexate.99  
Also, lifestyle factors such as alcohol use and smoking which are more prevalent in psoriasis 
can have a negative influence on development of carcinoma like oral cavity, esophagus, liver, 
pancreas, lung, kidney and breast cancer.95,100  
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Infections 
Data on the risk of both cutaneous and systemic infection in patients with psoriasis are 
limited. A large epidemiologic study revealed that patients with psoriasis have an increased 
resistance to cutaneous infections compared with controls and atopic dermatitis patients.101 
This finding has been related to an increased expression of antimicrobial peptides in psoriatic 
skin.102  
On the other hand, several studies have shown an association between streptococcal throat 
infections and the exacerbation of guttata psoriasis or chronic plaque psoriasis.103,104 Also, 
viral infections such as human immunodeficiency virus and hepatitis C can trigger or 
exacerbate psoriasis.105,106  
Immunosuppressive anti-psoriatic therapies such as methotrexate, cyclosporine and biologics 
also increase the risk of systemic infections.107 Particular attention is required for tuberculosis 
and appropriate vaccination should be given to psoriasis patients under immunosuppressive 
therapy.108  
Non-Alcoholic Fatty Liver Disease (NAFLD)  
NAFLD including a spectrum of conditions going from simple steatosis to steatohepatitis and 
cirrhosis, is now regarded as the hepatic manifestation of metabolic syndrome. Two studies 
showed an increased prevalence of NAFLD in psoriasis patients (38% and 47%) compared to 
control patients (28% and 28%).109,110 Also, psoriasis patients with NAFLD are more likely to 
have metabolic syndrome and a more severe degree of skin disease than those with psoriasis 
alone. Because of this comorbidity extra caution should be made when starting up hepatotoxic 
medication such as methotrexate in the psoriasis population.109,110  
Obstructive Sleep Apnea Syndrome (OSAS) 
Although data are limited with regard to the relationship between psoriasis and OSAS, 
common comorbidities (e.g. obesity) and similarities in inflammatory mediators give rise to a 
possible relationship between the two diseases. A preliminary study of 25 psoriasis patients 
and 19 patients with chronic bronchitis demonstrated a greater prevalence of OSAS in those 
with psoriasis than in the control group.111 Furthermore, a small study by Karaca et al studied 
the sleep quality of 33 psoriasis patients by means of polysomnography, of which 18 psoriasis 
patients (54,5%) were diagnosed with  OSAS.112 Physicians treating patients with psoriasis 
need to incorporate this comorbidity into their assessment of disease, especially in obese 
patients. 
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Chronic  Obstructive Pulmonary Disease (COPD)  
A large case-control study by Dreiher et al showed an significantly increased prevalence of 
COPD in psoriasis patients (5,7%; n=12 502) compared to control patients (3.6%; n= 24 287) 
(p <0.001). Several mechanisms for the association between psoriasis and COPD can be 
suggested. Firstly, psoriasis and COPD have a common risk factor i.e. cigarette smoking. 
Secondly, the chronic inflammatory state in both COPD and psoriasis can be the link between 
both diseases. Also, similar to patients with psoriasis, patients with COPD often have one or 
more components of the metabolic syndrome. Further prospective studies are needed to 
establish this association.113  
1.3 Health-related quality of life in psoriasis  
The impact of psoriasis on patient health-related quality of life (HRQOL) is major and has 
been well documented in the scientific literature.74,114,115 Measuring HRQOL provides a 
complementary assessment of the patient’s overall wellbeing because it defines the total 
impact of an illness and its therapy based on patient’s own perception.115 Different 
dimensions of HRQOL play a role in psoriasis. Firstly, the physical impact of psoriasis is 
profound. Disease severity in psoriasis is classically measured by Psoriasis Area and Severity 
Index (PASI), body surface area (BSA) or Physician's Global Assessment (PGA) judged by a 
physician. However, this clinical severity measurement does not always correlate with 
patient’s reported degree of disability. For example, patients with psoriasis of only the hands 
would be rated as mild based on the percentage of BSA involved, but the functional 
impairment would be great. In contrast, physical impact in HRQOL questionnaires is based on 
patient’s own perception and this has a strong correlation with the psychosocial impact of the 
disease. In addition, physical symptoms such as pruritus and scaling have a great impact on 
HRQOL.114,116 Secondly, the psychological burden in psoriasis, caused by lifelong distress of 
coping with psoriasis everyday, is tremendously. Feelings of embarrassment, helplessness, 
frustration and anger can lead to a depression. As a consequence, alcohol abuse, cigarette 
smoking, the use of tranquilizers, sleeping pills and antidepressants are seen more frequently 
in psoriasis patients.116 Thirdly, social stigmatisation and rejection common seen in psoriasis 
leads to avoidance behaviour. Sequential, social and occupational difficulties may occur, 
further decreasing their overall HRQOL.115-117  
HRQOL in psoriasis is most commonly assessed by means of self-report questionnaires. 
These can be divided into generic, dermatology-specific and psoriasis-specific quality of life 
questionnaires. Dermatology-specific questionnaires are preferable to generic ones because 
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they assess relevant dermatology-specific aspects of HRQOL and they are more sensitive to 
small changes in effects in patients with mild to moderate psoriasis. Examples of commonly 
used generic HRQOL questionnaires are Short Form-36 (SF-36) and EuroQol-5D (EQ-5D).118 
Dermatology life quality index (DLQI) and Skindex-29 are most frequently used 
dermatology-specific QOL questionnaires. In Table 5  the clinically important cutt-off scores 
for DLQI and Skindex-29 are given.3,4   
Tabel 5: Clinically important cutt-off values for Skindex-29 and Dermatology life quality index 
(DLQI)3,4 
Skindex-29 Scores Effect on patient's quality of life DLQI Scores 
Effect on patient's quality of 
life 
Symptoms 0-10 Mild 0-1 no  
  11-25 Moderate 2-5 small  
  ≥ 26 severe to very severe 6-10 Moderate 
Emotions 0-24 Mild 11-20 very large 
  25-49 Moderate 21-30 extremely large  
  ≥ 50 severe to very severe    
Functioning 0-10 Mild    
  11-32 Moderate    
  ≥ 33 severe to very severe   
 
For future research Skindex-17 is a promising questionnaire.119 Psoriasis-specific QOL 
questionnaires such as Psoriasis Disability Index (PDI), Psoriasis Life Stress Index (PLSI) 
and Salford Psoriasis Index (SPI) meet a great acceptance by patients but they prohibit 
comparisons with any other disease.118  All these questionnaires measure one point-in-time. 
Meanwhile, the Cumulatieve Life Course Impairment (CLCI) gives an overall effect of 
psoriasis over a patient’s life course, considering the associated clinical and psychological 
implications that result in an altered or impaired life potential.117  
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Figure 3 – Cumulative life course impairment (CLCI) occurs from an interaction between the burden 
of stigmatisation, physical and psychological co-morbidities; and coping strategies and external 
factors. Important impairment may occur in patients with ineffective coping strategies and little social 
support, even if they have a limited burden. This impairment may be lower in patients with effective 
coping strategies and strong social support networks, even if the burden is high. (Figure adapted from 
Kimball 2010)117 
 
1.4 Lifestyle factors in psoriasis 
1.4.1 Stress 
Increasing evidence shows that psychological stress can influence the course of psoriasis. 
Verhoeven et al showed that daily stressors affected the course of psoriasis severity and itch at 
moments when patients experienced a high level of daily stressors.120 In addition, they have 
shown a relationship between differences in individual stress reactivity and changes in disease 
outcome in patients with psoriasis. Patients with high levels of worrying and scratching seem 
most vulnerable to the influence of daily stressors, particularly at moments of high stress.121 
Furthermore, patients with persistently high levels of stressors seem to have lowered cortisol 
levels and may be particularly vulnerable to the influence of stressors on their psoriasis.122  
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A ‘brain–skin connection’ with local neuro-immuno-endocrine circuitry underlies the 
pathogenesis of psoriasis, triggered or aggravated by stress.123 Acute psychosocial stress is 
associated with an altered hypothalamus-pituitary-adrenal response124 and changes of immune 
functions in psoriasis which may be one potential explanation of how stress may trigger 
psoriatic eruption.125,126   
In addition, up to 60% of patients believe that the onset of their psoriasis was a result of 
psychological stress. The disease itself can cause psychological stress, creating a vicious 
cycle.127 Therefore, stress management can be important for psoriasis patients vulnerable to 
the influence of stressors on their skin disease. Different methods of stress management exist 
such as cognitive behavioural stress management91, mindfulness-based stress reduction128,129  
or physical activity.130 Also, biological changes can be seen with these methods of stress 
management. For example, in a randomised, controlled trial Davidson et al found changes in 
brain and immune function after 8-weeks mindfulness meditation in 41 healthy persons.131 
Additional research on this topic is needed.  
1.4.2 Obesity 
An association between obesity and psoriasis is well established. Not only is obesity 
associated with a higher incidence of psoriasis17,18 and greater severity18,132, but it also affects 
response to treatment.133 A randomised trial comparing cyclosporine to cyclosporine plus 
weight loss in obese patients with moderate-to-severe psoriasis demonstrated contributory 
effects of weight loss on treatment response.134 Also, complete remission after gastric bypass 
surgery has been reported in cases.135,136  
Several mechanisms explaining the association between psoriasis and obesity have been 
proposed, including increased social isolation, increased unhealthy dietary habits, increased 
alcohol consumption and decreased physical activity.133,137 
In addition, understanding hormonal and cytokine biology can also explain the association 
between psoriasis and obesity. Increased levels of leptin, IL-6 en TNF- α are contributing to 
the pro-inflammatory state in both psoriasis and obesity. In contrary, adiponectin is an anti-
inflammatory hormone that suppresses the effects of TNF-α, IL-6 and improves insulin 
sensitivity. This adipocytokine is decreased in obese psoriasis patients.138,139  
It would appear reasonable to suggest that weight loss, could contribute positively to reducing 
the pro-inflammatory state and improving the clinical course of obese patients with psoriasis. 
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1.4.3 Physical activity 
There is increasing evidence that physical activity plays an important role in psoriasis. 
Frankel et al showed in a study of US women, that vigorous physical activity was 
independently associated with a decreased risk of new-onset psoriasis. More specific, they 
found that participation in at least 20.9 metabolic equivalent task-hours per week of vigorous 
exercise, the equivalent of 105 minutes of running or 180 minutes of swimming or playing 
tennis, is associated with a 25% to 30% reduced risk of psoriasis. The reduced risk of incident 
psoriasis was not seen with low to moderate physical activity such as walking. This may be 
due to the effect of vigorous physical activity on systemic inflammation.140  
The mechanism whereby physical activity decreases psoriasis risk deserves further 
investigation. Physical activity is known to reduce chronic inflammation and particularly 
decreases levels of proinflammatory cytokines, such as tumor necrosis factor141 and 
interleukin 6.142  In addition, physical activity is known to upregulate adiponectin and 
downregulate leptin.143 These are two adipokines originating from adipose tissue and known 
to play a major role in psoriasis and obesity.70 Furthermore, the protective effects of physical 
activity could also be mediated through its effect on mood. Exercise reduces anxiety and 
stress and improves emotional well-being.144  
Thereby, it is shown that physical and psychosocial impairments common in psoriasis may 
make it problematic to adhere to physical activity. Three studies have found that 38%, 36% 
and 34% of psoriatics reported difficulty participating in sports.145-147 
Because of the importance of physical activity and the difficulty participating in sports for 
psoriasis patients, additional support on this matter should be given. For example, creating a 
setting for psoriasis patients to participate in sports can be a valuable solution. Future studies 
should aim to determine if physical activity interventions improve health related outcomes in 
psoriasis. 
1.4.4 Smoking 
Smoking increases the risk of development of psoriasis. Higher intensity and duration of 
smoking was associated with increased clinical severity of psoriasis.17,148-150 Chronic 
palmoplantar pustulosis – a subtype of psoriasis – has been shown to have the strongest 
association with smoking.149  
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Several mechanisms behind smoking’s negative impact on psoriasis have been proposed. 
Firstly, smoking-induced oxidative stress resulting from increased reactive oxygen species 
production along with insufficient capacity of antioxidant mechanisms may be involved in the 
pathogenesis of psoriasis.151 Secondly, psoriasis involves a neutrophil-predominant 
inflammatory infiltrate and smoking can alter the morphology and function of neutrophils.152 
Thirdly, genetic–environmental interactions involving smoking have been proposed. Duffin et 
al presented evidence that polymorphisms in the IL13/IL4 region (especially rs1800925*T) 
may be associated with protection from developing psoriatic arthritis and that this effect may 
be abrogated by smoking.153 Thus, smoking cessation may be an important target for 
prevention and management of psoriasis.154   
 
1.5 Adherence to therapy in psoriasis 
Poor adherence to therapy is a complex problem existing for many chronic diseases such as 
diabetes, hypertension and heart disease. This can result in poorer prognosis, more 
hospitalizations and significantly higher health care costs. Improving adherence to therapy - 
whether it be medication, behavioural or lifestyle changes- can lead to improved patient 
outcomes and reduced health care costs.155  
Especially in psoriasis, adherence to therapy is a major problem. Up to 50% of patients do not 
use their medication as prescribed.156 Several factors can influence patient’s adherence to 
therapy. (Figure 4) Patients characteristics, disease characteristics and treatment 
characteristics all influence medication adherence and treatment outcomes. Also, physician 
interaction and enabling factors are playing a role in this complex cycle.157  
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Figure  4 - Adherence to medication is influenced by multiple factors; HRQoL, Health-related quality 
of life. (Figure adapted from Feldman 2008)157 
 
For example, topical treatment regimens can be complex. Simplifying the treatment regimen 
by shorten the duration of treatment and advise once-daily application, can improve adherence 
and hence outcome. Besides, patient’s interaction with the physician plays a major role in 
treatment adherence. Good two-way communication and education of the patient about 
psoriasis and its therapy can establish a trusting relationship and higher level of adherence. 
Next to this, adherence to treatment increases before and after physician visits. Therefore, 
scheduling a follow-up visit shortly after treatment initiation may be of help.158 Another 
option to enhance adherence to therapy after treatment initiation is  regular phone calls by a 
health care provider. (e.g specialist nurse)155  
 Nurses are in a good position to occupy a key role in patients management. A dermatology 
specialist nurse can give additional education, support and be a point of contact for follow-up 
care throughout the long-term course of the disease.159,160 
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In conclusion, we may say that improving adherence to therapy in psoriasis is still at an early 
stage.  Future research is needed to find the right approach to promote adherence to therapy in 
patients with psoriasis.  
1.6 Conclusion 
In conclusion, we can say that psoriasis is not merely a skin disease but is associated with 
several comorbidities and an impaired health-related quality of life. A holistic and 
multidisciplinary approach with attention for lifestyle modifications and adherence to therapy 
is essential. In Chapter 2 we discuss the aims and outline of this thesis with focus on 
improving the quality of care for psoriasis patients. 
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Chapter 2: Aims and outline of this Thesis 
Aims 
The general objective of this research project is to improve the quality of care for psoriasis 
patients by evaluating following items in our patient population:  
Our first aim is to acquire new insights in the complex association between psoriasis, psoriatic 
arthritis and metabolic syndrome. Therefore, we performed a prospective, cross-sectional 
study in 123 psoriasis patients. The main objective of this study was to examine the difference 
in prevalence of metabolic disease burden between patients with psoriasis who lack arthritic 
manifestations and psoriatic arthritis patients. A better understanding of these associations 
may have implications for psoriasis management. (Chapter 3) 
Our second aim is to evaluate whether our educational programme has its added value in the 
care for psoriasis patients. Patient education and motivation play an increasingly important 
role in the long term management of psoriasis. We conducted a prospective, randomised 
controlled trial in 66 patients with psoriasis and atopic dermatitis to investigate whether our 
educational programme is of added value to medical therapy. Effect on disease severity and 
quality of life were measured as primary endpoints at different time points. Furthermore, level 
of depression, lifestyle changes and effect on medical consumption were followed during 9 
months. (Chapter 4) 
Lastly, we give an overview of updated relevant aspects in the clinical dermatological 
assessment of psoriasis patients, emphasizing the importance of a multidisciplinary and 
holistic clinical approach. In this review, a template is proposed which can be integrated in the 
currently used electronic patient file, thereby creating the potential of gathering information 
for future research. (Chapter 5) 
Outline 
In the last decade, the view on psoriasis as skin disease has shifted towards seeing it as a 
systemic disease with association of several comorbidities. In addition, substantial advances 
have been made in elucidating the molecular and immunological mechanisms of psoriasis. 
These improved insights into pathogenesis in psoriasis has resulted in major benefits for 
patients, including the introduction of several targeted therapies.1  
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Introduction of  health-related quality of life instruments in the assessment of disease severity 
has led to a greater awareness of the true impact of psoriasis. These have shown that the 
impact of psoriasis is similar to other chronic diseases, including hypertension, diabetes and 
depression, and is ranked as one of the diseases that has the greatest impact on physical and 
mental health.2 Due to these new insights, medical management of psoriasis has changed over 
the last decade. Lots of effort has been put in improving quality of care in psoriasis. 
Multidisciplinary collaboration receives more attention by setting up combined dermatology-
rheumatology clinics3 and psoriasis disease centers.4 There is also a greater focus on patient 
centered care which allows health-related quality of life to be integrated in clinical 
management. The hallmarks of this concept are education of the patient and an effective two-
way communication required to better integrate physician and patient perspectives. Patient 
centered care is especially valuable in psoriasis because of chronicity of the disease, lack of 
treatment adherence and need for lifestyle adjustments and psychological support.5  
Next to this, definition of treatment goals6 and establishment of treatment guidelines7-9 can 
improve quality of care in psoriasis. A recent review of the European Expert Working Group 
for Healthcare in Psoriasis (EEWGHP) defined following action points to improve quality of 
care for psoriasis patients (see Table 2).10 The ultimate goal is to provide early access to high 
quality care for all psoriasis patients and thereby preventing cumulative life course 
impairment.  
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Table 2: Actions points defined by EEWGHP as required from stakeholders or specific audiences to 
improve quality of care for psoriasis patients.10 
Actions Stakeholders/Audiences 
1. Raise awareness of psoriasis and ensure that it 
is officially recognised as a serious medical 
condition 
Patient advocacy groups, healthcare 
organisations, government, industry, academia, 
healthcare professionals 
2. Promotion the development, awareness and use 
of treatment guidelines 
Healthcare organisations, healthcare 
professionals, patient advocacy groups, European 
bodies 
3. Raise awareness of assessments tools and their 
standard use, whilst identifying the potential for 
new assessment tools 
Healthcare professionals, industry, healthcare 
organisations, academia 
4. Define treatment goals and associated 
management strategies and encourage patients to 
be involved in setting their individual goals and 
strategies 
Healthcare professionals, industry, healthcare 
organisations, patients 
5. Drive data collection on the impact of earlier 
intervention with systemic therapies and 
proactively manage psoriasis through provision of 
timely therapeutic monitoring and a 
multidisciplinary team approach to ongoing care 
Healthcare organisations, governments, industry, 
academia, primary and secondary care healthcare 
professionals, European bodies 
6. Drive patient advocacy groups engagement 
with guideline- and policy-making parties 
Healthcare organisations, governments, industry, 
healthcare professionals, health technology 
assessment agencies, patients, patient advocacy 
groups 
 
With our work we want to contribute to this improvement in quality of care in psoriasis by 
acquiring new insights in comorbidities, evaluating our educational programme and giving an 
overview of relevant aspects in the assessment of psoriasis patients.   
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Chapter 3: New insights in the presence of comorbidities in psoriasis 
Introduction 
Several comorbidities are frequently associated with psoriasis such as psoriasis arthritis, 
cardiovascular disease and psychiatric disease. These comorbidities are discussed in Chapter 
1 in more detail. Early detection of these comorbidities in psoriasis can improve outcomes.  
This can be accomplished by creating increased awareness and appropriate screening 
methods. Next to this, multidisciplinary collaboration makes early referral to a specialist 
possible.  
In the following chapter, we discuss the similarities and differences between psoriasis and 
psoriatic arthritis with respect to epidemiology, genetics, immunology and biomarkers. 
Furthermore, we present our first paper on the association of metabolic syndrome in psoriasis 
versus psoriasis arthritis.  
3.1 Psoriasis and psoriasis arthritis separate entities or one and the same?  
Increasing evidence arises for a common etiology of skin psoriasis (PsO) and psoriatic 
arthritis (PsA) based on shared genetic markers, common immunological features and 
epidemiological similarities.1 Although, the underlying factors which predispose patients to 
develop cutaneous or articular disease or both are unexplored. 
Early detection of  PsA can lead to better outcomes. Patients seen at a rheumatology clinic 
within two years of diagnosis have less joint damage progression compared to those with 
longer disease duration at first clinic visit.2 Therefore, next to screening questionnaires, 
biomarkers may be useful to screen PsO patients for PsA.3 
In this section, we discuss the similarities and differences between PsO and PsA with respect 
to epidemiology, genetics, immunology and biomarkers.    
Epidemiology 
PsO and PsA occur equally in men and women.4 The majority of the patients (circa 70%) 
develop PsO before PsA. In contrast, PsA precedes the onset of PsO by more than 1 year in 
circa 15% of cases.5 This last setting characterizes the so-called subset of psoriatic arthritis 
”sine psoriasis”.6 In addition, in another 15% the two conditions occur together within a 12 
months period.5 
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The correlation of skin and joint symptoms in patients with PsO and PsA can vary 
significantly. Early studies suggested that PsA was linked with more severe cases of  PsO.7 
On the contrary, Cohen et al showed that most patients with psoriatic arthritis have mild skin 
disease (n=221).8 Additional to this, Jones et al found no association between severity of skin 
lesions and severity of arthritis among 100 consecutive patients with PsA.9 However, a recent 
study found a highly significant correlation between skin and joint disease in 70 cases where 
the initial onset of both diseases was simultaneously.10  
Genetics 
A common genetic etiology for psoriasis and psoriatic arthritis has long been suspected. 
Associated HLA antigens for both diseases (B13, B17, B57, Cw6, DR7) have been described.  
However, there are several differences in susceptibility loci between PsO and PsA. In PsO 
there are associations with HLA B37 and in PsA with HLA B7, B27, B38, B39, CR4, DR4, 
DR5, DR8.1 HLA-Cw*0602 risk allele is stronger associated with PsO compared to PsA.11 In 
addition, multiple susceptibility loci (PSORS 1 – PSORS7) to PsO have been reported which 
were not consistently reproducible in PsA cohorts.12-14 Furthermore,  several genome-wide 
association studies have been published. Genes implicated in skin barrier function including 
LCE3, DEFB4, and GJB2 are playing an important role in PsO but not in PsA.15-17 Lastly, 
Bowes et al found 2 IL13 SNP (rs20541 and rs1800925) that were highly associated with 
susceptibility to PsA but not to PsO.18   
Immunology 
The inflammatory infiltrate in the skin and joints has been subject of detailed investigation. In 
both tissues there is a prominent lymphocytic infiltrate, localised in the epidermis and dermis 
of the skin and in the synovial fluid of the joints. T lymphocytes are most occurring 
inflammatory cells in the skin and joints. CD4+ Tcells are the most common lymphocytes in 
the tissues. In contrast with the synovial fluid compartment, where CD8+ Tcells are the most 
common lymphocytes.19,20 Also, specific vascular changes have been reported in psoriasis 
skin and synovial membrane. Angiogenesis is dysregulated and angiogenic growth factors are 
upregulated in both PsO and PsA.21 In addition, similarities in expression of neuropeptides in 
skin and joints have been described.22 This may suggest a common neurovascular pathway. 
Furthermore, it is likely that cytokines, especially TNF-α and many others, may be involved 
in driving the inflammation in both PsO and PsA.23  
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Biomarkers 
Chandran et al found that  increased serum levels of receptor activator of nuclear factor-κB 
ligand, tumor necrosis factor superfamily member 14, matrix metalloproteinase-3 and 
cartilage oligomeric matrix protein are independently associated with psoriatic disease (PsA 
and PsO). A combination of biomarkers -  high-sensitivity CRP (hs-CRP), osteoprotegerin 
(OPG), matrix metalloproteinase 3 (MMP-3) and the ratio of C-propeptide of type II collagen 
to collagen fragment neoepitopes (CPII/C2C)-  is independently associated with PsA. This 
combination was able to distinguish patients with PsA from patients with PsO. Although these 
biomarkers are promising, they still need validation in prospective studies.3 
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3.2 Paper 1: A cross-sectional study on the prevalence of metabolic syndrome in 
psoriasis compared to psoriatic arthritis. (Submitted to J Eur Acad Dermatol 
Venereol, 2012) 
Bostoen J.a,Van Praet L.b, Brochez L.a, Mielants H.b, Lambert J.a 
aDepartment of Dermatology and bDepartment of Rheumatology, Ghent University Hospital, Ghent, Belgium 
Abstract 
Background 
Increasing epidemiological evidence suggests associations between psoriasis, psoriatic 
arthritis and metabolic disease. Elucidating the complex relationship between these 
comorbidities may have important management implications. 
Objective 
The aim of this study was to examine the difference in prevalence of metabolic disease burden 
between patients with psoriasis who lack arthritic manifestations (PsO) and psoriatic arthritis 
patients (PsA). 
Methods 
We performed a cross-sectional study in 123 patients with psoriasis only (PsO) and psoriasis 
arthritis (PsA).  Metabolic syndrome was defined using the new criteria developed by the 
International Diabetes Foundation (IDF) in 2004. Therefore, clinical examination, standard 
survey and fasting blood samples were collected.  
Results 
One hundred and four patients were analysed of which 49 PsO and 55 PsA patients. We found 
that prevalence of the metabolic syndrome according to the IDF criteria was significantly 
higher in the PsO (44,9%) compared to the PsA group (25,5%) (p=0,037). Looking closer at 
the individual components of the metabolic syndrome, this difference can mainly be attributed 
to the significantly higher prevalence of abdominal obesity in PsO (83,7%) versus PsA 
(65,5%) (p= 0,034). For other individual components of the metabolic syndrome such as 
triglycerides, high density lipoproteins, hypertension and plasma glucose, we could not show 
statistically significant differences between the groups.  
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Conclusion 
Metabolic syndrome is more prevalent in patients with PsO than in PsA patients, mainly 
determined by the higher prevalence of abdominal obesity in PsO compared to PsA group. 
These findings suggest that screening for metabolic syndrome should be considered especially 
in group of PsO patients.  
Introduction 
Psoriasis is a chronic inflammatory skin disease with a genetic and immunologic background. 
Its prevalence has been estimated at 2% of the population.1 Psoriasis is a disabling disease 
affecting the physical and emotional well being of patients, and its effect on quality of life is 
similar to that seen within other major medical diseases such as diabetes, rheumatoid arthritis, 
and cancer.2 Recently, it is increasingly being recognized that psoriasis is probably associated 
with other co-morbidities. In 1% up to 39% of patients, psoriasis may be accompanied by 
arthritis. The majority of the patients (circa 70%) develop psoriasis before articular 
involvement; in contrast arthritis precedes the onset of psoriasis by more than 1 year in circa 
15% of cases, and in another 15% the two conditions occur together within a 12 months 
period.3 
Increasing epidemiological evidence suggests independent associations between psoriasis and 
cardiovascular and metabolic disease. This association increases with increasing disease 
severity.4 Among patients with rheumatological disease (rheumatoid arthritis, ankylosing 
spondylitis, and psoriatic arthritis), psoriatic arthritis patients show the highest risk for 
presence of metabolic syndrome, in particular obesity, impaired glucose tolerance, and 
hypertriglyceridemia.5 
The basis for the relationship between psoriasis, psoriatic arthritis and metabolic syndrome is 
complex, with the effects of chronic systemic inflammation, psychosocial issues, and 
potential adverse effects of therapies likely to be important.  A better understanding of these 
associations may have management implications.  
The main objective of this study was to examine the difference in prevalence of metabolic 
disease burden between patients with psoriasis who lack arthritic manifestations (PsO) and 
psoriatic arthritis patients (PsA). 
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Patients and Methods 
We performed a prospective, cross-sectional study in patients with psoriasis only (PsO) and 
psoriasis arthritis (PsA). 123 patients were recruited from 3 different sources: dermatology 
clinic of the Ghent University Hospital (n=43), rheumatology clinic of the Ghent University 
Hospital (n=41) and patient advocacy groups (n=39). Data collection and analysis were 
performed during the period from January 2011 through May 2012. Eligible criteria were: 1) 
patients who fulfilled the ClASssification criteria for Psoriatic ARthritis (CASPAR)6 defined 
by a rheumatologist or were diagnosed with skin psoriasis by a dermatologist; 2) age ≥ 18 
years; and 3) patients who were able to give informed consent. The study was approved by the 
ethics committee of the Ghent University Hospital. 
In a face-to-face interview using a standard data collection protocol all patients were 
questioned about their medical history (including items related to psoriasis, with and without 
arthritis) as well as current and past medication, comorbidities and known risk factors. Blood 
pressure was measured twice and the average of 2 blood pressure readings was calculated. 
Body weight, body height, and waist circumference were also measured. Skin disease severity 
was determined by the Psoriasis Area and Severity Index (PASI) and nail abnormalities were 
investigated. Fasting blood was taken for assay of glucose, lipid levels (total cholesterol, high-
density lipoprotein [HDL] and low-density lipoprotein [LDL] cholesterol, and triglycerides 
level) and inflammatory parameters. 
Metabolic syndrome was defined using the new criteria developed by the International 
Diabetes Foundation (IDF) in 2004.7 This definition was based on a consensus between 
previous existing definitions of the WHO diabetes group, European Group for the Study of 
Insulin Resistance and US National Cholesterol Education Program: Adult Treatment Panel 
III. Ethnic-specific waist circumference cut-offs were incorporated into the definition. The 
criteria comprise central obesity (waist circumference ≥94 cm in men or ≥80 cm in women), 
plus two of the following: elevated triglycerides (≥150 mg/dL) or specific treatment for this 
lipid abnormality, reduced high-density lipoprotein cholesterol (<40 mg/dL for men; <50 
mg/dL for women) or specific treatment for this lipid abnormality, elevated blood pressure 
(≥130 mmHg systolic or ≥85 mmHg diastolic) or treatment of previously diagnosed 
hypertension, and elevated fasting plasma glucose (≥100 mg/dL) or previously diagnosed type 
2 diabetes. The use of waist circumference as parameter for obesity is preferred above body 
mass index because the latter lacks consideration of body composition and gender 
differences.8 
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Statistics 
Power calculation showed a total of 110 patients were needed for this cross-sectional study in 
order to obtain a 90 percent probability to detect a 0,25 prevalence difference between 2 
groups at a two-sided 0,05 significance level. Data were analyzed by using the Statistical 
Package for Social Sciences software, version 19. Chi-square test and Mann-Whitney U test 
were used to compare proportions between groups. Univariate and multivariate logistic 
regression models were used to calculate the odds ratio (OR) for metabolic syndrome. P < 
0.05 was considered significant. 
Results 
One hundred and ten patients were assessed for eligibility. Six patients were excluded because 
diagnosis of psoriatic arthritis according to CASPAR criteria was not fulfilled. One hundred 
and four patients were analysed of which 49 had psoriasis (PsO) and 55 psoriasis arthritis 
(PsA) (Fig. 1).  
The characteristics of the included study population are described in Table 1. Both groups are 
comparable concerning age, onset and duration of psoriasis. All patients with psoriatic 
arthritis also had psoriasis of the skin, except for 1. The majority of these patients developed 
skin manifestations before articular involvement (n=44, 81%).   
In the PsO group 40,8% of the patients were treated systemically compared to the PsA group 
in which 81,8% of patients was under systemic therapy (Chi-square test; p<0,001). There 
were more patients on cardio-protective medication in the PsO group, especially lipid-
lowering drugs and anticoagulants. Median PASI is significantly higher in the PsO [5,2 (IQR 
2,5-11,6)] versus the PsA patients [3,4 (IQR 0,6-5,5)] (Mann-Whitney U test; p<0,05).  
Family history for skin psoriasis is 71% versus 57% in PsA compared to PsO and for psoriasis 
arthritis 33% compared to 4% in PsA versus PsO. There were more smokers in the PsO group 
(30,6%) compared to PsA group (18,2%) and the use of daily alcohol was higher in PsA 
patients (32,7% vs 26,5%) but this did not reach significance. Physical activity level was 
almost the same in both groups: approximately half of the patients performed moderate to 
intensive physical activity. Psychological distress (as asked by history) was higher in the PsO 
group (67%) compared to PsA group (42%) (Chi-square test; p<0,01) and antidepressant use 
was higher in the PsO group but did not reach significance. (14,3% vs 7,3%).  
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The prevalence of metabolic syndrome according to the IDF criteria was significantly higher 
in the PsO (44,9%) compared to the PsA group (25,5%) (Chi-square test; p=0,037). Looking 
closer at the individual components of the metabolic syndrome, this difference was mainly 
attributable to the significantly higher prevalence of abdominal obesity in PsO (83,7%) versus 
PsA (65,5%) (Chi-square test; p= 0,034). For other individual components of the metabolic 
syndrome such as triglycerides, high density lipoproteins, hypertension and plasma glucose, 
we could not show statistically significant differences between the groups.  
The prevalence of the metabolic syndrome in the analysed population could be influenced by 
other factors such as age, disease severity (PASI), disease duration, systemic therapy or 
systemic inflammation (CRP).  Older age was significantly correlated with a higher 
prevalence of metabolic syndrome [OR=1,1 (1.0,1.1)].  No significant difference was seen in 
prevalence of the metabolic syndrome for the other factors. Univariate and multivariate 
analyses adjusting for these factors reveiled persistent differences between PsA en PsO (Table 
2).   
PsA patients (n=55) can be divided in different types according to clinical pattern: 
oligoarticular (n=21) or polyarticular (n=17) peripheral disease and axial disease with (n=13) 
or without (n=4) associated peripheral arthritis. We did not find significant differences in 
prevalence of metabolic syndrome nor the individual components of the metabolic syndrome 
in the different subtypes of PsA.   
PsO patients treated with biologics (n=13) have significantly higher prevalence of the 
metabolic syndrome compared to PsA patients treated with biologicals (n=26)  [OR=11,1 
(2.3,54.0)] and compared to PsO patients not treated with biologics (n=36) [OR=6,7 
(1.5,28.8)].  PsA patients treated with biologicals (n=26) had a longer use of biologicals (4,8 
years ±4,3) compared to the PsO patients on biologicals (n=13) (2,5 years ±1,9).  
Discussion 
In this study we observed a significantly higher prevalence of the metabolic syndrome 
according to the IDF criteria in patients with psoriasis of the skin compared to patients with 
psoriasis arthritis. Looking closer at the different components of metabolic syndrome, the 
difference was mainly attributable to a significantly higher prevalence of abdominal obesity in 
PsO versus PsA. This association was even enhanced after multivariate adjustments for 
confounding factors such as age, disease severity, disease duration, systemic therapy and 
systemic inflammation.  
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To our knowledge this is the first study that compares prevalence of metabolic syndrome in 
PsO compared to PsA.  Little data exist on individual components of the metabolic syndrome 
or cardiovascular morbidity between PsO and PsA. Husted et al found that the prevalence of 
hypertension was significantly higher in PsA patients than in PsO patients after multivariate 
analysis.9 Ahlehoff et al reported a similar cardiovascular risk in patients with severe PsO and 
PsA.10 
Our results show high prevalence of hypertension in both PsO (85,7%) and the PsA (80%) 
group compared to what is known from literature (38.8%).11 That may be due to three factors: 
firstly, high mean age of our study population (49,5±12,9 years), secondly white coat 
hypertension may overestimate the prevalence of hypertension in our study and thirdly due to 
the stringent criteria of hypertension (≥130/85) by IDF definition. Accordingly, Langan et al 
found a prevalence of hypertension in 87,9% of the psoriasis population compared to 59,5% 
in the control group with similar criteria and age range.4 We believe a definition with strict 
criteria for cardiovascular disease is clinically important because severe psoriasis and/or 
psoriatic arthritis carry a risk of cardiovascular disease comparable to that of patients with 
diabetes mellitus.10  
According to literature, the correlation of skin and joint symptoms in patients with psoriasis 
and psoriatic arthritis can vary considerably. Early studies suggested that arthritis was more 
common in more severe cases of psoriasis.12 In contrast, Cohen et al showed that most 
patients with psoriatic arthritis have mild skin disease.13 Consistent with the last study, we 
found a median PASI that was significantly higher in PsO compared to PsA patients.  
A limitation of our study is the difficulty of defining our groups, PsO versus PsA patients. 
Although, we assured that clinically we made the best distinction between those groups by 
appointing a dermatologist and a rheumatologist specialised in this matter, we can not be 
certain of our distinction between the groups because of two reasons: First of all, there are no 
serologic tests available to aid in the diagnosis of psoriatic arthritis such as rheumatoid factor  
in rheumatoid arthritis.14 Classification of PsA was based on CASPAR criteria but this has the 
disadvantage that early PsA can be missed.15 Secondly, PsO patients can develop arthritis in 
the future although most patients have a long disease duration of psoriasis (23 years), so 
definition of the groups might change over time.  
Several factors may be the cause of the complex association between psoriasis, psoriatic 
arthritis and metabolic syndrome. Firstly, the psychological burden associated with psoriasis 
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can make it more difficult to watch lifestyle behaviour such as diet and have a negative 
influence on metabolic syndrome.  In this study, the psychological impact was higher in the 
PsO than PsA group. Secondly, we cannot exclude the influence of past or current medication 
on metabolic syndrome. For example, acitretin use can be associated with lipid 
abnormalities.16 So far, there is limited evidence on the role of biologics on the prevalence of 
metabolic syndrome in psoriasis.17 In this study, PsO patients treated with biologics have 
higher prevalence of the metabolic syndrome compared to PsA patients treated with 
biological or compared to PsO patients not treated with biologics. This implies that skin 
psoriasis plays an independent role in the risk of metabolic syndrome. Thirdly, a different 
genetic background between PsO and PsA patients could explain this difference in prevalence 
of metabolic syndrome. For example, overlapping susceptibility loci has been demonstrated in 
skin psoriasis and diabetes type 2 (CDKAL-1).18  Fourthly, adipokines such as adiponectin, 
leptin, originating from adipose tissue, could play a pathogenetic role in the association 
between psoriasis and metabolic disease. Leptin is upregulated and adiponectin 
downregulated in both psoriasis and obesity.19,20 At last, also systemic inflammation might 
have an influence on prevalence of metabolic syndrome.21 Unfortunately, because of the 
cross-sectional design of the study, no causal relationship can be deduced from this analysis.  
The metabolic burden is high in the psoriasis population, especially in the PsO group (44,9 
%). This comorbidity is associated with an increased cardiovascular risk beyond traditional 
risk factors.22 Additional to this, we suspect an undertreatment of the cardiovascular risk 
factors in our study population. Accordingly, Ahlehoff et al and Kimball et al showed an 
undertreatment of cardiovascular risk factors in psoriasis patients.23,24 
Therefore we and others21,25 recommend that physicians treating moderate to severe psoriasis 
are instructed on how to screen for comorbid conditions, more specifically metabolic 
syndrome. Patient education with regard to lifestyle modifications (such as physical activity 
and diet) should be integrated in the general approach of psoriasis patients at risk.26 
Acknowledgments  
The study has been financially supported by Abbott. 
 Chapter 3: New insights in the presence of comorbidities in psoriasis 
 
56 
 
 
Tables 
Table 1: Characteristics of the included study population, psoriasis (PsO) compared to psoriatic 
arthritis patients (PsA) (n=104) 
Variables PsO (n=49) PsA (n=55) 
Gender (male),n (%) 29(59,2) 38(69,1) 
Age (years), mean (± SD) 49,4 (±12,7) 49,7 (±13,3) 
Duration of psoriasis (years), mean (± SD) 23,0 (±14,4) 22,9 (±11,4) 
Duration of psoriasis arthritis (years), mean (± SD)   14,5 (±11,1) 
Age at onset of psoriasis (years), mean (± SD) 26,1 (±12,4) 26,7 (±12,9) 
PASI, median (IQR) 5,2 (2,5-11,6) 3,4 (0,6-5,5) 
CRP (mg/dl), median (IQR) 0,2 (0,1-0,35) 0,2 (0,1-0,5) 
Current smokers, n (%) 15(30,6) 10(18,2) 
Current daily drinkers, n (%) 13(26,5) 18(32,7) 
Therapy psoriasis and psoriatic arthritis     
Topical therapy,n (%) 37(75,5) 27(49,1) 
Light therapy,n (%) 5(10,2) 3(5,5) 
Systemic therapy,n (%) 20(40,8) 45(81,8) 
        Biologics,n (%) 13(26,5) 26(47,3) 
        Duration on biologics (years), mean (± SD) 2,5 (±1,9) 4,8 (±4,3) 
        Methotrexate,n (%) 2(4,1) 19(34,5) 
        Leflunomide,n (%) 0(0) 8(14,5) 
        Sulfasalazine,n (%) 0(0) 1(1,8) 
        Acitretin,n (%) 4(8,2) 0(0) 
        Fumaric acid esters,n (%) 1(2) 0(0) 
        Past biologics,n (%) 10(20,4) 11(20) 
        Past methotrexate,n (%) 20(40,8) 26(47,3) 
Cardio-protective medication     
Lipid-lowering medication,n (%) 8(16,3) 5(9,1) 
Antihypertensive medication,n (%) 13(26,5) 12(21,8) 
Anti-diabetic medication,n (%) 1(2) 1(2) 
Anticoagulants,n (%) 6(12,2) 4(7,3) 
SD= standard deviation; IQR= interquartile range; PASI= Psoriasis Area and Severity Index; CRP= C-
reactive protein. 
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Figures 
 
Fig.1 Flow diagram of the progress of the patients through the trial: patients enrolled, assessed for 
eligibility and included in the study. 
CASPAR = Classification criteria for psoriatic arthritis. 
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Chapter 4: Evaluating the added value of the Ghent University educational 
programme 
Introduction 
Patient education plays an increasingly important role in the long term management of 
psoriasis. As discussed in the introduction, psoriasis has a major impact on quality of life and 
is associated with several comorbidities and lifestyle factors. Besides, a great problem of non-
adherence to therapy exists in psoriasis patients. In addition to this, psoriasis patients find it 
difficult to self-manage their disease. Ersser et al found that there is a need for educational 
programmes who enables psoriasis patients to develop the knowledge, skills and confidence 
to self-manage effectively. Key features of  such an educational programme are resource 
efficient, individualized, person-centred and systematic.1 
The ultimate goal of our educational programme is to enable patients to achieve good quality 
of life despite having a chronic skin disease. In the following chapter, we present our 
educational programme for chronic skin diseases in paper 2 and our randomized, controlled 
trial for psoriasis and atopic dermatitis patients in paper 3. 
Reference 
1 Ersser SJ, Cowdell FC, Latter SM et al. Self-management experiences in adults with mild-
moderate psoriasis: an exploratory study and implications for improved support. Br J 
Dermatol 2010; 163: 1044-9. 
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4.1 Paper 2: A novel multidisciplinary educational programme for patients with 
chronic skin diseases: Ghent pilot project and first results. (Published in Arch 
Dermatol Res, 2011) 
J. Bostoena*, J. Lamberta*, B. Geusensa, J. Bourgoisb, J. Booneb, D. De Smedtc, L. Annemansc 
*contributed equally to this work 
a Department of Dermatology, Ghent University Hospital, Ghent, Belgium 
b Centre of Sports Medicine, Ghent University Hospital, Ghent, Belgium 
c Department of Public Health, Ghent University Hospital, Ghent, Belgium 
Abstract 
Chronic inflammatory skin disorders have a major impact on patients’ health related quality 
of life. Preliminary studies to date have suggested that additional educational and 
psychological training programmes may be effective in the management of chronic skin 
diseases, although more rigid methodology is needed. Our purpose was to investigate the 
effect on quality of life of a novel multidisciplinary educational programme for patients, 18 
years or older, with chronic skin diseases. The 12-week intervention encompasses cognitive 
education on skin and general health issues, and stress-reducing techniques. Quality of life 
questionnaires were used to assess the participants at baseline and at the end of the program. 
These comprehend Dermatology Life Quality Index (DLQI), Skindex-29, Psoriasis Disability 
Index (PDI) and Quality of Life Index for Atopic Dermatitis (QoLIAD). Fifty-five patients 
participated in six programmes since 2006. Forty-three patients completed the programme. 
Overall, compared to baseline, DLQI (n=39) improved by 5.64 points (p<0.001; SD ±6.09), 
Skindex-29 (n=27) by 19.67 points (p<0.001; SD ±17.37), PDI (n=9) improved by 7.44 points 
(p=0.019; SD ±7.60) and QoLIAD (n=13) improved by 4.39 points (p=0.036; SD ±6.69) by 
the end of the intervention.  Preliminary results show that quality of life of patients with 
chronic skin diseases improved significantly after participation to the programme. These 
positive initial results are stimulating to set up a prospective controlled randomised trial 
investigating the impact on quality of life, the clinical efficacy and the cost-effectiveness of 
this educational intervention programme.   
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Introduction  
Patients with chronic inflammatory skin disorders like psoriasis, atopic dermatitis, chronic 
urticaria, etc. are prone to psychological distress.[11] The chronic relapsing character of these 
diseases and the need for continuous, sometimes unsatisfactory treatment causes frustration 
and disappointment in patients, which in turn might negatively influence the disease course. 
In periods of stress, exacerbations are often triggered or worsened. The importance of the 
brain-skin interaction in the etiology of these diseases has therefore received much attention 
the last years.[2,3,7] Increasing the knowledge of the patient about their skin disease and 
treatment can stimulate participation in the treatment decision and this can have positive 
effects on patients satisfaction, compliance and health outcomes, as shown by Renzi et al.[17] 
In Ghent, we came up with the concept of an educational programme that could be added to 
our standard treatment approaches for chronic dermatoses. Offering more support and 
education in the format of group sessions will improve the comprehension of the skin 
condition, change the attitude towards the disease, improve the adherence to prescribed 
therapy and improve quality of life. The novelty of this programme is that it is open to all 
diagnoses and that it combines cognitive educational sessions, stress reduction techniques and 
additional skin workshops. Our programme runs 2 or 3-hour sessions twice weekly for 12 
weeks.  It was set up in 2006 and runs twice yearly. Our purpose was to investigate the effect 
on quality of life of this educational programme for patients with chronic skin diseases. 
Preliminary results of six runs of the programme are presented here.  
Patients and methods  
Patient population  
Patients from any gender or race with a chronic skin disease such as psoriasis, atopic 
dermatitis or other types of eczema, chronic urticaria, acne, hidradenitis suppurativa, 
vitiligo… can enter the programme. Age range for inclusion is from 18 years onwards. 
Content of the educational programme 
The educational programme consists of 2-hour sessions twice weekly for 12 weeks. An 
interdisciplinary team of trainers is involved: dermatologist; dermatologic nurse; pharmacist; 
psychiatrist; psychologist; dietician; philosopher; training expert; sports, mindfulness and 
yoga teacher. An overview of the activities, and their share in the whole programme, is given 
in Table 1. The programme activities can be divided into 4 groups. 
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1. Specific information on skin disease conditions 
In the first 1-h session, a dermatologist gives basic medical information on all diagnoses 
present in the patient group. Topics such as the definition of the different diseases, basic 
pathogenetic mechanisms, clinical symptoms, prognosis, and treatment of a given skin disease 
are carefully explained.  
Furthermore, three skin care sessions of 2-h are offered. A pharmacist together with a 
dermatologic nurse present information on structure, biological and social functions of skin; 
specific skin disease problems such as xerosis, itch and scaling are tackled.   
2. Stress-reduction techniques  
Physical training Patients get acquainted with a variety of group and individual sports during 
12 weeks, 1 hour per week. The aim is to enhance the motivation for physical training on a 
regular basis and let patients find what type of sports is best of fit for them. This training 
scheme is preceded by a physical fitness assessment as a method for screening health risk 
prior to exercise and sport.[4,24] 
Yoga Yoga combines many stress-reducing techniques, including exercise and learning to 
control the breath, clear the mind and relax the body. This group training is given in 9 
sessions of 1 hour each. [22]  
Mindfulness-based stress reduction This technique is a behavioural intervention based on 
insight meditation. It aims to be alert for itch, pain and other sensations or moods and it 
prevents to be carried away by negative thoughts and reaction patterns. This is educated in 8 
sessions of 2,5 hours each on a weekly basis. [16] 
3. Information sessions on life style factors and psycho-dermatology 
(a)  Diet 
Two information sessions on composing a balanced diet are given by a dietician. The lessons 
accentuate the importance of healthy and varied nutrition. Moreover specific topics about 
nutrition and skin are highlighted, such as food allergy, psoriasis and the metabolic 
syndrome….  
(b)  Responsible physical training 
In one session the elements of building condition and responsible training are explained. This 
session is given by a training expert. 
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(c)  Sleep hygiene 
A session about sleep hygiene highlights the importance of good sleep and  discusses sleep 
disorders. The different treatment options to optimize sleep are discussed. This session is 
given by a psychiatrist specialized in sleeping disorders.  
(d)  Smoking cessation 
In this session more insight is given in the association between smoking and skin diseases. 
Moreover, smoking cessation counseling is offered to the participants that smoke.   
(e)  Substance abuse  
Substance abuse is sometimes the consequence of the burden of a chronic disease which again 
has a negative influence on the course of the disease. During this session, information is given 
about alcohol abuse, the short- and longterm effects and treatment. This session is given by a 
psychiatrist. 
(f)  Psycho-dermatology 
A session psycho-dermatology informs about the common underlying psychopathological 
disorders that often accompany chronic dermatoses, and ways to counter them. This session is 
given by a psychiatrist. 
(g) Practical philosophy 
Two philosophical sessions are included in the programme to inspire the patients on a 
paradigm shifting with regard to their disease. These lessons are given by a philosopher. 
Of all cognitive interventions, including the skin information sessions, a syllabus is offered to 
the patients.  
4. Feedback 
The dermatologist also sees the patients halfway the programme on an individual basis to 
answer more individual questions, and at the end, in a group evaluation session.  
Evaluations 
Patients complete the following validated, self-administered quality of life questionnaires 
before start of the programme and immediately after the programme: Dermatology life quality 
index (DLQI), Skindex-29, Psoriasis disability index (PDI) and Quality of Life Index for 
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Atopic Dermatitis (QoLIAD). DLQI and Skindex-29 are dermatology-specific quality of life 
instruments. DLQI consists of 10 questions concerning patients’ perception of the impact of 
skin diseases on different aspects of their quality of life over the last week. The results of a 
few studies investigating the clinical meanings of the DLQI score show a minimal clinical 
important difference between 2.2 and 6.9 depending on the skin disease.[5] The Skindex-29 
consists of 30 items divided in 3 scales, assessing burden of symptoms, social functioning and 
emotional state. The questions refer to the previous 4-week period, and scores are given on a 
5-point scale, from ‘never’ to ‘all the time’.[1] PDI and QoLIAD are disease specific quality 
of life instruments for psoriasis and atopic dermatitis respectively. The PDI is a 15-item scale 
that specifically addresses self-reported disability in areas of daily activities, employment, 
personal relationships, leisure and treatment effects.[14] The QoLIAD consist of 25 questions 
and measures the impact of atopic dermatitis on quality of life in adults. In these four 
questionnaires a higher score indicates a greater negative impact of the skin disease on quality 
of life.[23] 
The physical fitness assessment preceding participation to the programme measures body 
mass index (BMI), fat percentage and the physical condition of the patients based on VO2 
max. For the determination of the fat percentage, the Parizkova-method was used. In this 
method the skin fold thickness is measured at ten different locations on the body. For the 
determination of the VO2 peak, the subjects perform an incremental ramp exercise test on a 
cycle ergometer (Lode Excalibur Sport, The Netherlands) with a rate of increase in work rate 
ranging between 10 and 25 Watt.min-1 depending on the anthropometrics and the fitness level 
of the individuals. The pulmonary gas exchange is registered breath-by-breath by means of 
the Jaeger Oxycon Pro (Germany) and the VO2 max is determined as the highest VO2 over a 
period of 30s. The condition of the participants based on the VO2 max is divided into five 
categories (weak, low, average, good and very good) according to gender and age.  
Statistical analysis  
Statistical analysis of the data were performed using PASW software version 18. The paired 
student t-test was used to compare continued variables. Parametric tests could be performed 
because the continue variables were distributed normally. 
Results  
Currently six runs of the programme have been completed. A total of 55 patients participated. 
Forty-three patients completed the programme, twelve dropped out, including eight men and 
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four women. (nine psoriasis, one atopic dermatitis, one prurigo, and one acne). The reasons 
for drop-out were lack of time, depression, infection or locomotor disability.  
Included diagnoses were: psoriasis, atopic dermatitis, prurigo, alopecia areata, pemphigus, 
hidradenitis suppurativa, acne , chronic urticaria, morphea and seborrhoic dermatitis. In Table 
2 the number of patients are given that started and completed the programme, completed the 
physical fitness assessment and completed the quality of life questionnaires. Mean age of the 
total group (n=55) was 45 years (range 25-69 years). The physical fitness test preceding 
participation to the programme revealed the following values for BMI, fat percentage and 
patient physical condition (based on VO2 max ): for women (n=28), mean BMI was 26.3  
kg/m² (SD ±5.4), mean fat percentage was 26.5% (SD ±6.6) and mean VO2 max was 27.5 
ml/min.kg (SD ±7.5). For men (n=25), mean BMI was 25.9 kg/m² (SD ±4.0), mean fat 
percentage was 19.4% (SD ±6.0) and mean VO2 max was 35.9 ml/min.kg (SD ±9.8). The 
mean condition in women is weak in 21%, low in 46%, average in 25% and good in 7%. In 
men the mean condition is weak in 12%, low in 24%, average in 32%, good in 28% and very 
good in 4%. The mean BMI of psoriasis patients was 27.5 (n=25, SD ±4.9) and mean BMI of 
atopic dermatitis patients was 23.8  (n=15, SD ±3.0).  
Quality of life  
For 39 patients a DLQI score and of 27 patients a Skindex-29 score was obtained before and 
after the programme. Overall, mean DLQI improved by 5.64 points (p<0,001; SD ±6.09)  and 
mean Skindex-29 by 19.67 points (p<0,001; SD ±17.37).   
Additionally, a PDI score was obtained from nine psoriasis patients and a QoLIAD score was 
obtained from 13 atopic dermatitis patients before and after the programme. In psoriasis 
patients, mean DLQI (n=15) improved by 3.93 points (p=0.015; SD ±5.50), mean Skindex-29 
(n=9) improved by 23.33 points (p=0.020; SD ±24.15) and mean PDI (n=9) improved by 7.44 
points (p=0.019; SD ±7.60). In atopic dermatitis patients mean DLQI (n=15) improved by 
6.33 points (p=0.003; SD ±6.73), mean Skindex-29 (n=14) improved by 17.50 points 
(p<0,001; SD ±9.97) and  mean QoLIAD (n=13) improved by 4.39 points (p=0.036; SD 
±6.69).  
The mean values of the questionnaires before and after the programme for each diagnosis are 
given in Table 3 and Table 4. 
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Discussion 
In the present article, we have described the goals, content and preliminary results of a novel 
educational programme that we introduced as an additional therapy to the standard treatment 
for chronic skin diseases.  
The results of the physical fitness test before the programme showed overweighed patients 
(n=53, mean BMI = 26.1 kg/m²). Mean fat percentage in men (19.4%) and women (26.5%) 
was higher than in normal healthy population (17% in men and 23% in women). The mean 
condition in women was weaker than in men, however, 36% of male participants have also a 
weak or low condition. The results of the physical condition test therefore emphasizes the 
importance of managing lifestyle factors such as diet and exercise.   
Furthermore, validated questionnaires revealed that the health related quality of life 
significantly improved after the intervention. Specifically, women with atopic dermatitis 
(n=9) seemed to benefit most from the programme with regard to quality of life. 
An important goal of our educational programme is to improve patients adherence to therapy. 
Good evidence shows that office visits drive patients adherence behaviour. Even independent 
of the content of the visits, our twice weekly visits could have an effect on patients 
compliance to treatment.  
Several concepts of educational and behavioural interventions have been described for skin 
diseases, in particular for psoriasis[12,15], atopic dermatitis[9,18] and chronic 
pruritus.[6,10,20] These programmes have in common that they contain education on the skin 
disease, education on lifestyle factors and stress-reducing techniques but they slightly differ in 
their approach depending on the skin disorder. They are conducted ranging from 1 to 6 
sessions during up to 6 weeks. The overall results of these studies show improved quality of 
life and clinical outcome compared with a control group. 
The major difference with our concept is the intensity and the diversity of our programme: our 
programme runs 2-hour sessions twice weekly for 12 weeks including education about skin 
diseases, skin care work-shops, education about lifestyle and stress-reduction techniques such 
as yoga, physical training and mindfulness-based stress reduction. Limitations to our 
preliminary data are lack of a control group and lack of a clinical outcome measurement. 
Finally, we could not control for changes in other aspects of the patients’ managements, such 
as changes in the pharmacological therapy. 
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Conclusions and future perspectives  
The objective of our programme was to support patients in the self-management of their skin 
disease in a holistic manner. Education about skin diseases and stress-reduction techniques 
were the basic elements of our programme. In addition we wanted to accentuate the approach 
of lifestyle factors as diet, exercise, sleep, alcohol and smoking.[19] Lifestyle factors can 
influence the course of skin diseases especially in psoriasis in which an increased incidence of 
the metabolic syndrome and cardiovascular disease has recently drawn attention.[13] 
With the description of the elaboration of the programme and its preliminary outcome we 
want to be of help in defining and setting up future standardized preferably multi-center trials 
with a critical set-up for evaluation. Warsi et al.[21], Ersser et al.[9] and Chida et al.[8] 
emphasize the need for rigorously designed trials with well-validated interventional 
instruments, maximal reduction of possible bias, and better description of important variables 
such as patient educational level, disease duration and severity and social support.  
This initiative for patients with chronic dermatoses was experienced as a valuable addition to 
classical treatment. Quality of life with regard to specific skin problems was improved. These 
positive initial results are stimulating to set up a prospective controlled randomised trial 
investigating the impact on quality of life, the clinical efficacy and the cost-effectiveness (in 
light of restricted health care budgets) of this educational intervention programme, in  a group 
of patients with chronic skin diseases. In view of all this, we call for a multi-center European 
study in this field. 
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Tables 
 
Table 1:  An overview of the activities and their part in the whole programme. 
Overview of activities Teacher Number of 
sessions 
Duration 
one session 
Total 
duration 
 
1. Specific information on skin 
disease conditions 
1.a Information session about 
skin diseases 
1.b Skin care 
 
 
 
 
Dermatologist 
 
Pharmacist and 
dermatologic nurse 
 
 
 
1 
 
3 
 
 
 
60min 
 
120min 
 
 
 
 
 
1h 
 
6h  
 
2. Stress-reduction techniques 
2.a  Physical training 
2.b  Yoga 
2.c  Mindfulness-based stress  
       Reduction 
 
 
 
Sports teacher 
Yoga teacher 
Mindfulness 
teacher 
 
 
 
12 
9 
8 
 
 
60min 
60min 
150min 
 
 
12h 
9h 
20h 
 
 
 
3. Information sessions on life 
style and psychodermatology 
3.a  Diet 
3.b  Responsible physical 
training 
3.c  Sleep hygiene 
3.d  Smoking cessation 
3.e  Substance abuse  
3.f  Psycho-dermatology 
3.g Practical philosophy 
 
 
 
Dietician 
Training expert 
Psychiatrist 
Psychologist 
Psychiatrist 
Psychiatrist 
Philosopher 
 
 
 
2 
1 
1 
1 
1 
1 
2 
 
 
 
60min 
60min 
90min 
60min 
90min 
90min 
60+90min 
 
 
 
2h 
1h 
1.5h 
1h 
1.5h 
1.5h 
2.5h 
 
4. Feedback  
4.a   Individual 
4.b  In group 
 
 
 
Dermatologist 
Dermatologist 
 
 
 
1 
1 
 
 
15min 
1h 
 
 
15min 
1h 
Total: 
60h15min 
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Table 2: Number of patients that started and ended the programme, completed the physical fitness 
assessment, and completed the quality of life questionnaires before and after the programme: 
Dermatology life quality index [DLQI], Skindex-29, Psoriasis disability index [PDI] and Quality of 
life index for atopic dermatitis [QoLIAD]. 
Diag-
nosis 
Number of patients 
 
Started 
program-
me 
Completed 
physical 
fitness 
assess-
ment 
Ended 
program-
me 
Completed 
DLQI 
before and 
after 
Completed 
Skindex-
29 before 
and after 
Completed 
PDI 
before and 
after 
Completed 
Qoliad 
before and 
after 
Psoriasis 26 25 17 15 9 9 0 
Atopic 
dermati-
tis 
16 15 15 15 14 0 13 
Prurigo 3 3 2 2 0 0 0 
Alope-
cia 
areata 
2 2 2 1 1 0 0 
Pemp-
higus 2 2 2 1 1 0 0 
Hidrade-
nitis 
suppu-
rativa 
2 2 2 2 1 0 0 
Acne 1 1 0 0 0 0 0 
Chronic 
urticaria 1 1 1 1 0 0 0 
Mor-
phea 1 1 1 1 0 0 0 
Seborr-
hoic 
derma-
titis 
1 1 1 1 1 0 0 
Total 
55 (25 
men/ 30 
women) 
53 (a) 43 39 (b) 27 (c) 9 (d) 13 (e) 
(a) Two patients did not take part in the physical fitness assessment at the start of the programme; (b) 
Of  43 patients who completed the programme, 4 patients  did not fill out DLQI questionnaire; (c) 
Only 27 of 43 patients filled out Skindex-29 because this questionnaire was only introduced since the 
second programme; (d) Only 9 of the 17 psoriasis patients who ended the programme filled out a PDI 
because this questionnaire was only introduced since the second programme; (e) Of 15 atopic 
dermatitis patients who completed the programme, two patients did not complete QoLIAD. 
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Table 3: Mean values and standard deviation (±SD) of Dermatology life quality index [DLQI] and 
Skindex 29 outcomes are given for each diagnosis. 
Diagnosis Mean 
DLQI 
before  
(±SD) 
Mean 
DLQI 
after 
(±SD) 
Mean 
Improve-
ment in 
DLQI 
(±SD) 
Mean 
Skindex 29 
before 
(±SD) 
Mean 
Skindex 29 
after 
(±SD) 
Mean 
Improve-
ment in 
Skindex 29 
(±SD) 
Psoriasis 9.87 (±6.63) 
5.93 
(±6.01) 
3.93 
(±5.50; 
*p=0.015) 
54.78 
(±22.47) 
31.44 
(±19.99) 
23.33 
(±24.15; 
*p=0.020) 
Atopic 
dermatitis 
14.80 
(±6.77) 
8.47 
(±3.29) 
6.33 
(±6.73; 
*p=0.003) 
70.36 
(±11.96) 
52.86 
(±10.30) 
17.50 
(±9.97; 
*p<0.001) 
Prurigo 9.50 (±9.19) 
3.00 
(±0.00) 
6.50 
(±9.19; 
*p=0.500) 
   
Alopecia areata 6.00 0.00  38.00 19.00  
Pemphigus 9.00 11.00  46.00 52.00  
Hidradenitis 
suppurativa 
17.50 
(±3.54) 
6.00 
(±0.00) 
11.50 
(±3.54; 
*p=0.136) 
91.00 40.00  
Acne       
Chronic 
urticaria 18.00 10.00     
Morphea 14.00 0.00     
Seborrhoic 
dermatitis 6.00 2.00  37.00 25.00  
Total 12.23 (±6.75) 
6.59 
(±4.82) 
5.64 
(±6.09; 
*p<0.001) 
62.59 
(±19.25) 
42.93 
(±17.68) 
19.67 
(±17.37; 
*p<0.001) 
Mean improvement in DLQI and Skindex-29 is calculated by the difference in mean values before and 
after the programme . * significance value 
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Table 4: Mean values and standard deviation (±SD) of Psoriasis disability index [PDI] and Quality of 
life index for atopic dermatitis [QoLIAD] outcomes are shown.  
 Mean before 
(±SD) 
Mean after 
(±SD) 
Mean improvement (±SD) 
Psoriasis : PDI 12.00 (±6.78) 4.56 (±5.25) 7.44 (±7.60;*p=0.019) 
Atopic dermatitis: QOLIAD 13.15 (±3.85) 8.77 (±5.60) 4.39 (±6.69;*p=0.036) 
Mean improvement in PDI and QoLIAD is calculated by the difference in mean values before and 
after the programme . * significance value 
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4.2 Paper 3: An educational programme for patients with psoriasis and atopic 
dermatitis: a prospective randomized controlled trial. (Accepted in Br J 
Dermatol, 2012) 
J. Bostoena, S. Brackea, S. De Keysera,  J. Lamberta 
a Department of Dermatology, Ghent University Hospital, Ghent, Belgium 
Summary 
Background Patient education in addition to standard treatment, with the aim of affecting care 
through courses is a relatively new concept in dermatology. Here we introduce a randomized 
controlled trial (RCT) regarding a previously described 12-week educational programme for 
chronic skin diseases.   
Objective The primary objective of the RCT was to measure the effect of an educational 
programme on disease severity and quality of life in patients with psoriasis or atopic 
dermatitis.  
Methods We recruited 50 patients from the Ghent University Hospital. Patients with 
diagnosed psoriasis or atopic dermatitis were randomized (1:1) to the intervention or control 
group. The clinical outcome was measured by two blinded observers using Psoriasis Area and 
Severity Index (PASI), Scoring Atopic Dermatitis or the Eczema Area and Severity Index. 
Quality of life was measured by dermatology-specific quality of life questionnaires. There 
was a follow-up period of 9 months.  
Results We found that disease severity and quality of life improved significantly for patients 
with psoriasis (n=29) but not for patients with atopic dermatitis (n=21) at 3 months. Patients 
in the intervention group showed a significant reduction in mean PASI (P=0.036), mean 
Dermatology Life Quality Index (P=0.019) and in mean Psoriasis Disability Index (P=0.015), 
compared with the control group at 3 months. This improvement continued for at least 6 
months, i.e. 3 months after the intervention, but was lost at follow-up after 9 months.   
Conclusion Evaluating this form of educational programme, by means of a single-centre RCT, 
indicates its added value in the longer term management of psoriasis. 
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Introduction 
Chronic skin diseases, such as psoriasis and atopic dermatitis, have a profound negative 
impact on  patient’s quality of life.1,2  Because treatment is highly self-demanding, we see a 
low compliance to therapy, resulting in poor clinical outcomes.3,4 Therefore, patient education 
and motivation plays an increasingly important role in the long-term management of chronic 
skin diseases. Successful education increases patient satisfaction and improves health 
outcomes and adherence to treatment.5,6  As more studies are needed within this context, we 
set up further research on our previously described group-based educational programme.7 We 
conducted a prospective, single-blinded, randomized controlled trial (RCT) in adult patients 
with psoriasis and atopic dermatitis, to investigate whether our educational programme is of 
added value to medical therapy. Effect on disease severity and quality of life were measured 
as primary end points at different time-points. Furthermore, the level of depression, lifestyle 
changes and the effect on medical consumption were followed over 9 months. 
Patients and methods  
Patient population and study procedures 
From February 2010 to 2011, 50 patients were recruited from three different sources: Ghent 
University Hospital (n=18), patient advocacy groups (n=26) and peripheral dermatologists 
(n=6). Patients older than 18 years with psoriasis or atopic dermatitis were eligible to 
participate in the trial. At inclusion, patients were checked for diagnosis by a dermatologist. 
Exclusion criteria were other severe illnesses, psychiatric disorders and cognitive disorders. 
The patients were randomized (1:1) to the intervention or control group. This procedure 
involved computer-generated randomization of lists in which allocation was indicated, and 
stratified by diagnosis using a block size of two. Sequentially numbered envelopes were used 
by the investigator to assign patients to the intervention or control group. Patients assigned to 
the intervention group participated in the educational programme while still receiving medical 
therapy, whereas patients assigned to the control group received only medical therapy. Three 
runs of the programme were included in the trial: 14 patients started in spring 2010, 23 in 
autumn 2010 and 13 in spring 2011. Patients were assessed at four study visits: before the 
start of the programme (baseline), after the programme (3 months) and at two follow-up visits 
at 6 and 9 months after the start. The study was approved by the local ethical committee 
(registration number B67020097924) and was registered on http://www.clinicaltrials.gov 
(NCT01077882).  
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Intervention: group-based educational programme 
The 12-week educational programme consisted of 2-h sessions twice a week, including 
several components: (i) education on the patient’s skin disease; (ii) education on a healthy 
lifestyle; (iii) application of stress-reducing techniques and (iv) feedback. The first part 
included an information session on the patient’s skin disease given by a dermatologist, and 
three skin care sessions given by a dermatological nurse and pharmacist. The second part 
contained education on diet, responsible physical training, sleep hygiene, smoking, substance 
abuse, psychodermatology and practical philosophy, given by a team of trainers: a dietician, 
training expert, psychiatrist,  psychologist and philosopher. The third part consisted of weekly 
physical training, yoga and mindfulness meditation taught by a sports, yoga and mindfulness 
teacher. The fourth and final part contained two feedback sessions with a dermatologist. 
Detailed content of the programme is described in Lambert et al.7 
Primary outcomes 
Disease severity 
Two clinicians performed assessments of disease severity at the four study visits and were 
blinded for randomization. The clinical severity of psoriasis was assessed by the Psoriasis 
Area and Severity Index (PASI),8 and the severity of atopic dermatitis by Scoring Atopic 
Dermatitis (SCORAD) and the Eczema Area and Severity Index (EASI).9 Clinicians were 
trained to define the PASI, SCORAD and EASI before start of the trial. The level of 
agreement between both clinicians’ assessments on PASI, SCORAD and EASI was very 
good. The intraclass correlation coefficient was 0.86 (95% confidence interval (CI) 0.72-0.94) 
for PASI, 0.89 (CI 0.74-0.96) for SCORAD and 0.92 (CI 0.82-0.97) for EASI. 
Quality of life  
Patients completed the following validated, self-administered quality-of-life questionnaires at 
the four study visits: Dermatology Life Quality Index (DLQI),10 Skindex-29,11 Psoriasis 
Disability Index (PDI)12 and Quality of Life Index for Atopic Dermatitis (QoLIAD).13 DLQI 
and Skindex-29 are dermatology-specific quality of life instruments. DLQI is a historical 
comparator and focuses on disability, thereby not fully capturing the emotional aspects of 
patients’ lives. Skindex-29 is a more sensitive instrument for different dimensions of quality 
of life, including emotions. PDI and QoLIAD are disease-specific quality-of-life 
questionnaires. More information about the questionnaires is given in Lambert et al.7 
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Secondary outcomes 
Depression severity 
The Beck Depression Inventory (BDI) is a self-completed questionnaire with 21 questions. It 
is one of the most widely used instruments for measuring depression severity.14 Patients were 
categorized as having minimal (0-9), mild (10-18), moderate (19-29) or severe (30-63) 
depression. BDI scores were collected during four study visits. 
Lifestyle 
Patients were queried monthly for changes in smoking behaviour and physical activity. 
Physical activity was categorized as: sedentary activity (i), light physical activity (walking, 
biking) < 4h weekly (ii),  or at least 4h weekly (iii), and moderate physical activity (sports) < 
4h weekly (iv), or at least 4h weekly (v).15 Stress was examined by the Everyday Problem 
Checklist during four study visits.16 Patients were categorized as having a low (men ≤ 6 , 
women ≤ 4), normal (men 7-36, women 5-33) or high (men ≥37, women ≥34) stress level. 
Medical consumption and cost-effectiveness evaluation 
The medical therapy of the patients was divided into topical therapy, systemic therapy, 
combination of topical and systemic therapy or no therapy. Topical therapy included: 
corticosteroids with or without calcipotriol, calcineurin inhibitors, tar ointment and hydration. 
Systemic therapy included: methotrexate, ciclosporine, acitretin, oral corticosteroids and 
ultraviolet (UV)-B. Patients were asked about changes in medical therapy monthly. Also, 
medical consumption  was followed,i.e. costs for medication and doctor visits related to the 
management of the skin disease. EuroQol-5D (EQ-5D) questionnaires were used as a 
standardized instrument to measure health outcomes. For cost-utility analysis, the gain in 
quality-adjusted life years utility was plotted against time, using the area under the curve 
approach (cost in euro/EQ-5D gain). 
Statistics 
Power calculation showed that 34 patients were needed for this RCT. There is an 80% 
probability that the study would detect a treatment difference at a 0.05 significance level if the 
mean difference between treatments is 2 and the standard deviation is 2.  Data were analysed 
using SPSS software (SPSS Inc., Chicago, IL, U.S.A.). Mixed modeling analysis was 
performed to identify differences in time between the intervention and control groups for each 
outcome variable. These data were presented as mean and 95% CI. Intraclass correlation 
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coefficient was the measured level of agreement between both clinicians. The Spearman 
correlation coefficient measured  the correlation between quality of life and disease severity.   
Results  
Patient population 
Fifty patients participated in our trial, 29 with psoriasis and 21 with atopic dermatitis. There 
were 24 men and 26 women. The mean age was 39.6 ± 12.2 years, with a range of 21-63 
years. The mean duration of disease was 19.5 ± 11.1 years. At baseline, the average disease 
severity was mild for psoriasis; mean PASI was 7.7 ± 3.9. For atopic dermatitis, the average 
disease severity was moderate; mean SCORAD was 38.9 ± 16.3 and mean EASI was 11.1 ± 
9.3. The average quality of life for the total group was moderately to severely affected at 
baseline; mean DLQI was 8.5 ± 5.5 and mean Skindex-29 was 44.4 ± 16.8. Beck depression 
inventory showed a mean value of 9.8 ± 7.4, which represents a minimally depressive state. 
The highest educational attainment of the total group was low in 4%, medium in 38% and 
high in 58%; 57% were professionally active and 43% were professionally inactive (including 
students and pensioners); 71% had a multiperson household and 29% were living alone. 
Regarding treatment modalities, 76% of the patients were on topical therapy, 2% on systemic 
therapy, 14% on topical and systemic therapy and 8% had no therapy at baseline. Table 1 
shows the baseline characteristics of the patients in the intervention and control groups.  
Up to 3 months, there were nine dropouts, and a further three patients dropped out during the 
following 6 months. Reasons for dropout in the intervention group included lack of time, the 
programme being too intensive and moving house. In the control group, worsening of skin 
disease and loss of motivation were reasons given for dropout. Figure 1 shows a flow diagram 
of progress through the phases of the trial. 
Primary outcomes 
Disease severity and quality of life improved significantly after participation in the 
programme in the psoriasis group, but not in the atopic dermatitis group. These effects were 
maintained for at least 6 months but were lost at 9 months follow-up. Moreover, we saw a 
moderate correlation between quality of life and disease severity in the patients with psoriasis 
and atopic dermatitis.  At baseline, the Spearman correlation coefficient between PASI and 
DLQI was 0.6, and between SCORAD and DLQI was 0.5.   
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Disease severity and quality of life in patients with psoriasis 
We analysed data from 29 patients with psoriasis at 3 months. At 6 and 9 months, data from 
28 patients with psoriasis were analysed. One patient was excluded from analysis because her 
condition deteriorated severely due to stress caused by workplace bullying. 
Psoriasis area and severity index 
At 3 months: intervention patients showed significant reduction (P=0.036) in mean PASI 
going from 8.4 (CI 6.0-10.8) at baseline to 6.8 (CI 4.3-9.3) at 3 months, compared with the 
control group, which had mean PASI going from 7.1 (CI 4.8-9.4) at baseline to 8.1 (CI 5.8-
10.4) at 3 months.  
At 6 months: intervention patients showed significant reduction (P=0.017) in mean PASI 
going from 8.6 (CI 5.8-11.4) at baseline to 6.5 (CI 3.6-9.4) at 3 months ,and 5.9 (CI 3.0-8.9) 
at 6 months compared with the control group, which showed mean PASI going from 7.1 (CI 
4.6-9.7) at baseline to 8.1 (CI 5.6-10.7) at 3 months and 7.8 (CI 5.2-10.3) at 6 months. 
At 9 months: intervention patients showed reduction in mean PASI going from 8.6 (CI 5.6-
11.6) at baseline to 6.5 (CI 3.3-9.8) at 3 months, 6.0 (CI 2.7-9.2) at 6 months and 7.0 (CI 3.8-
10.3) at 9 months, compared with the control group, which showed mean PASI going from 
7.1  (CI 4.3-9.9 ) at baseline to 8.1 (CI 5.3-10.9) at 3 months,  7.8 (CI 5.0-10.6) at 6 months 
and 7.0 (CI 3.8-10.3) at 9 months, but this did not reach significance (P=0.116, Fig. 2a) 
Dermatology life quality index 
At 3 months: patients in the intervention group showed significant reduction (P=0.019) in 
mean DLQI going from 8.4 (CI 5.6-11.2) at baseline to 4.4 (CI 1.3-7.4) at 3 months, 
compared with the control group, which showed mean DLQI going from 6.6 (CI 3.9-9.3) at 
baseline to 6.4 (CI 3.6-9.2) at 3 months.  
At 6 months: patients in the intervention group showed reduction in mean DLQI going from 
8.0 (CI 5.0-11.0) at baseline to 4.8 (CI 1.4-8.2) at 3 months and 4.7 (CI 1.3-8.0) at 6 months, 
compared with the control group, which showed mean DLQI going from 6.6 (CI 3.8-9.4) at 
baseline to 6.4 (CI 3.5-9.3) at 3 months and 6.9 (CI 4.1-9.8) at 6 months, but this did not reach 
significance (P=0.089). 
At 9 months: intervention patients showed reduction in mean DLQI going from 8.0 (CI 4.9-
11.1) at baseline to 4.8 (CI 1.4-8.2) at 3 months, 4.7 (CI 1.3-8.0) at 6 months and 4.0 (CI 0.6-
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7.4) at 9 months, compared with the control group, which showed mean PASI going from 6.6 
(CI 3.7-9.5) at baseline to 6.4 (CI 3.5-9.3) at 3 months, 6.9 (CI 4.0-9.8) at 6 months and 5.8 
(CI 2.9-8.8) at 9 months, but this did not reach significance (p=0.100, Fig. 2b) 
Psoriasis disability index 
At 3 months: intervention patients showed significant reduction (P=0.015) in mean PDI going 
from 9.0 (CI 5.0-13.0) at baseline to 4.3 (CI 0.1-8.4) at 3 months compared with the control 
group, which had mean PDI going from 7.6 (CI 3.8-11.5) at baseline to 6.7 (CI 2.9-10.6) at 3 
months.  
At 6 months: intervention patients showed significant reduction (P=0.020) in mean PDI going 
from 8.8 (CI 4.5-13.0) at baseline to 4.5 (CI 0.1-9.0) at 3 months and 4.2 (CI -0.3-8.6) at 6 
months, compared with the control group, which showed mean PDI going from 7.6 (CI 3.7-
11.6) at baseline to 6.7 (CI 2.7-10.7) at 3 months and 7.3 (CI 3.3-11.3) at 6 months. 
At 9 months: intervention patients showed significant reduction (P=0.021) in mean PDI going 
from 8.8 (CI 4.3-13.2) at baseline to 4.5 (CI -0.1-9.1) at 3 months, 4.1 (CI -0.5-8.7) at 6 
months and 4.9 (CI 0.3-9.5) at 9 months, compared with the control group, which showed 
mean PDI going from 7.6 (CI 3.6-11.7) at baseline to 6.7 (CI 2.6-10.8) at 3 months, 7.3 (CI 
3.2-11.4) at 6 months and 7.4 (CI 3.3-11.6) at 9 months (Fig. 2c). 
Skindex-29 
No significant differences in Skindex-29 were seen between the intervention and control 
groups of patients with psoriasis. 
Disease severity and quality of life of atopic dermatitis  
We analysed data of 21 atopic dermatitis patients. No significant differences were seen 
between intervention and control group of atopic dermatitis for SCORAD, EASI, DLQI, 
Skindex-29 nor for QoLIAD.  
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Secondary outcomes 
Depression severity 
At 9 months, we analysed depression data from 29 patients with psoriasis. Patients in the 
intervention group showed a significant reduction (P=0.029) in mean BDI going from 12.3 
(CI 8.3-16.4) at baseline to 10.5 (CI 6.1-14.9) at 3 months, 9.1 (CI 4.7-13.5) at 6 months and 
6.1 (CI 1.7-10.5) at 9 months, compared with the control group, which had mean BDI going 
from 7.4 (CI 3.5-11.3) at baseline to 6.3 (CI 2.3-10.3) at 3 months, 8.1 (CI 4.1-12.0) at 6 
months and 7.3 (CI 3.2-11.3) at 9 months (Fig. 3). No significant differences for BDI were 
seen between the intervention and control groups for atopic dermatitis.   
Lifestyle  
Patients were queried on a monthly basis for changes in smoking behavior and physical 
activity. At baseline 13 patients were smokers (26%), of whom seven were randomized to the 
intervention group.  In the intervention group one patient stopped smoking after 3 months and 
one patient reduced to half the amount of cigarettes after 6 months. There were no changes in 
smoking behavior in the control group (n=6). Figure 4 shows the physical activity of the 
patients. The intervention group had a significantly higher physical activity level (P=0.035) 
than the control group during the entire study. At baseline, 64% of participants agreed on the 
negative influence of stress on their skin disease. The Everyday Problem Checklist (n=27) 
revealed low stress levels in 7.4%, normal stress levels in 44.4% and high stress levels in 
48.1% at baseline. However, we could not show significant differences in stress level between 
the control and intervention groups during the study. 
Medical consumption and cost-effectiveness evaluation 
Treatment interventions were allowed in both intervention and control groups. We monitored 
treatments by questionnaire and found no major differences between study arms over the 
period of the study (Table 2). We could not show significant differences in medical 
consumption between the control and intervention groups over the period 
of study. EQ5D values in the intervention group were not significantly better than in the 
control group at 6 months. Cost-utility analysis taking into account programme cost per 
patient and medical resource use per individual patient did not show cost-effectiveness at 6 
months. 
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Discussion  
In this RCT, at 3 months we found that our educational programme contributed to an 
improved disease severity and quality of life in patients with psoriasis. This improvement 
continued for at least 6 months, i.e. 3 months after the intervention, and was not related to 
major changes in medical therapy or influence of seasonal variation. Furthermore, an 
improvement in physical activity was seen in the intervention group but not in the control 
group.  Lastly, there was a longer positive effect on the depression status of patients with 
psoriasis. 
These findings support previous studies showing that patient education contributes to 
improved quality of life and clinical outcomes. In a multicenter RCT, Staab et al.17 showed 
that education for children with atopic dermatitis resulted in an improved quality of life and 
disease severity (n=992). Also, Fortune et al.18 found that a cognitive-behavioural symptom 
management programme for adult patients with psoriasis is beneficial in the management of 
psoriasis (n=93). De Bes et al.5 critically evaluated studies regarding educational programmes 
in patients with chronic skin diseases conducted between 2000 and 2008. Interventions that 
were more intensive and were delivered over a longer time scale (3 months or more) were 
more successful than briefer interventions. 19 
Important limitations of our study are the influence of confounding factors such as changes in 
therapy. Treatment interventions were not restricted in either the intervention or control 
group. Most patients were receiving topical therapy, as they had mild disease. We monitored 
treatments by questionnaire and found no major imbalances between study arms (Table 2), 
but we cannot exclude an influence of minor changes in therapy. Furthermore, the use of self-
administered quality of life questionnaires could lead to bias because patients are not blinded 
for the treatment allocation.   Nevertheless, bias by seasonal variation was reduced by 
staggering recruitment across seasons. There were 27 patients participating in spring and 23 
participating in autumn.  
No attempt was made with regard to our educational programme on eliciting the effects of 
individual components of the intervention. It would be interesting to study this in the future, 
especially with regard to psoriasis. 
Evaluating this form of educational programme, through the means of a single-centre RCT, 
indicates its added value in the longer term management of psoriasis. We cannot provide a 
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satisfactory explanation for the absence of effect in patients with atopic dermatitis. Certain 
disease-specific factors in psoriasis, such as metabolic comorbidities and susceptibility to 
addiction, might make diet and substance abuse of greater importance for patients with 
psoriasis than for patients with atopic dermatitis. However, we believe that these skin diseases 
have enough common ground with regards to their need for education. 
Further research is needed on how education is best offered, especially as regards the 
frequency of contacts and the intervals between them. As the beneficial effects seems to wane 
after 6 months after the end of the programme, and as the programme is perceived to be very 
intensive, it might be an option to offer components on a more continuous basis. We do 
believe that the group (vs. individual) format offers an advantage, and can in practice be better 
reconciled with the time-consuming aspects of organizing patient education. 
 In conclusion, our data indicate that this format of patient education deserves more 
investigation in order to obtain more robust data, especially in psoriasis. 
What’s already known about this topic? 
Patient education plays an increasingly important role in the long-term management of 
chronic skin diseases, such as psoriasis and atopic dermatitis. 
What does this study add? 
Evaluating this form of educational programme, by means of a prospective randomized 
controlled trial, indicates its added value in the long-term management of psoriasis. 
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Tables 
 
Table 1:  Baseline characteristics of patients in the intervention and control group. 
Variables Intervention  Control  
Gender: M/F (%) 48/52 48/52 
Diagnosis: psoriasis/atopic dermatitis (%) 60/40 56/44 
Age (years), mean (± SD) 38,5 (±12,3) 40,6 (±12,2) 
Duration of disease (years), mean (± SD) 18,9 (±11,0) 20,1 (±11,4) 
Age at onset of disease (years), mean (± SD) 19,6 (±17,3) 20,5 (±17,4) 
Education: low/medium/high (%) 4/22/74 4/52/44 
BMI, mean (± SD) 24,4 (±4,2) 25,3 (±4,9) 
PASI, mean (± SD) 8,9 (±4,3) 7,1 (±3,8) 
SCORAD, mean (± SD) 38,9 (±18,0) 38,8 (±15,5) 
EASI, mean (± SD) 11,9 (±10,9) 10,4 (±8,1) 
DLQI, mean (± SD) 9,7 (±6,0) 7,5 (±5,0) 
Skindex29 total, mean (± SD) 45,5 (±16,1) 43,3 (±17,7) 
Skindex29 symptoms, mean (± SD) 58,1 (±15,4) 55,8 (±18,4) 
Skindex29 emotions, mean (± SD) 48,9 (±19,6) 49,0 (±22,7) 
Skindex29 functioning, mean (± SD) 35,2 (±20,4) 30,8 (±21,4) 
Qoliad, mean (± SD) 9,1 (±5,6) 9,6 (±6,1) 
PDI, mean (± SD) 9,0 (±6,8) 7,6 (±7,8) 
BDI, mean (± SD) 11,3 (±8,2) 8,4 (±6,5) 
BMI, Body mass index; PASI, Psoriasis Area and Severity Index; SCORAD, Scoring Atopic 
Dermatitis; EASI, Eczema Area and Severity Index; DLQI, Dermatology Life Quality Index; 
QoLIAD, Quality of Life Index for Atopic. 
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Table 2: The numbers (n) of patients undergoing particular types of medical therapy (topical, 
systemic, combination of topical and systemic therapy, no therapy) over the time of the study in the 
intervention and control groups, and by diagnosis. 
    Intervention Control 
Time point Type of therapy N n 
  Psoriasis Atopic dermatitis Psoriasis 
Atopic 
dermatitis 
 Baseline Topical 9 8 12 9 
  
Systemic - - 1 - 
  
Combination 2 2 1 2 
  
No 4 - - - 
 
Total 15 10 14 11 
 3 months Topical 5 7 12 8 
  
Systemic - - - - 
  
Combination 2 1 - 2 
 
No 2 1 1 - 
  
Total 9 9 13 10 
 6 months Topical 4 6 12 7 
  
Systemic - - - - 
  
Combination 2 1 - 2 
 
No 2 1 1 - 
  
Total 8 8 13 9 
 9 months Topical 3 7 10 7 
  
Systemic - - 1 - 
  
Combination 2 1 1 1 
 
No 3 - 1 - 
  
Total 8 8 13 8 
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Figures 
 
 
Fig.1 Flow diagram of the progress through the phases of the trial. aDrop-outs ;b Excluded from 
analysis; PSO, patients with psoriasis; AD, patients with atopic dermatitis 
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Fig.2a Disease severity of psoriasis, as assessed by Psoriasis Area and Severity Index (PASI), for 
intervention patients (blue columns) and control patients (red columns) at baseline, 3, 6 and 9 months 
follow-up. All values are mean and 95% confidence interval. *P <0.05 
 
 
Fig.2b Quality of life of psoriasis, as assessed by Dermatology Life Quality Index (DLQI), for 
intervention patients (blue columns) and control patients (red columns) at baseline, 3, 6 and 9 months 
follow-up. All values are mean and 95% confidence interval. *P <0.05 
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Fig.2c Quality of life of psoriasis, as assessed by Psoriasis Disability Index (PDI), for intervention 
patients (blue columns) and control patients (red columns) at baseline, 3, 6 and 9 months follow-up. 
All values are mean and 95% confidence interval. *P <0.05 
 
 
Fig. 3 Mean depression scores for psoriasis, as assessed by Beck Depression Inventory (BDI), for 
intervention patients (blue columns) and control patients (red columns) at baseline, 3, 6 and 9 months 
follow-up. All values are mean and 95% confidence interval. *P <0.05 
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Fig. 4 The intervention group has significant more physical activity (p=0.035) than the control group 
during the 9 months of the study. Physical activity: 1, sedentary; 2, light <4h/week; 3, light >4h/week; 
4, moderate <4h/week;  5, moderate >4h/week. 
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Chapter 5: Updated approach to psoriasis management and follow-up 
5.1 Paper 4: A comprehensive approach to psoriasis management in the 
dermatological practice: a template for patient report anno 2012. (Submitted to J 
Am Acad Dermatol, 2012) 
DeCoster E.a, Bostoen J.a, van Geel N.a, Lapeere H.a, Lambert J.a 
aDepartment of Dermatology, Ghent University Hospital, Ghent, Belgium 
Abstract  
Psoriasis is a common chronic inflammatory skin disease, with complex interactions between 
genetic, immunological, systemic and environmental factors. Several comorbidities have been 
associated with psoriasis, such as immune-mediated inflammatory diseases, cardiovascular 
and metabolic diseases, different types of cancer and psychosocial problems. In addition, it 
should be mentioned that some of the medications in psoriasis has potentially severe side 
effects, warranting good pretreatment screening and therapy follow-up.  
Consequently this implies that dermatologists need to address several health-related aspects 
when assessing psoriasis patients, going far beyond just optimal skin care. This article offers 
an overview of the various relevant aspects in the clinical dermatological assessment of 
psoriasis patients, emphasizing the importance of a multidisciplinary and holistic clinical 
approach. It can be used as a template for good clinical practice in psoriasis.  
Introduction 
Psoriasis is a common chronic inflammatory skin disease, approximately affecting 2% of the 
population1. It is characterized by intense proliferation and abnormal differentiation of 
keratinocytes, resulting in erythematous plaques and scaling. Complex interactions exist 
between genetic, immunological, systemic and environmental factors. Furthermore, several 
disorders have been associated with psoriasis. These comorbidities frequently only become 
clinically manifest several years after the beginning of psoriasis and tend to occur more often 
in more severe psoriasis 2. Therefore, dermatologists need to approach psoriasis as a 
multisystem disorder, with health-related aspects going beyond the skin. Regular follow-up 
with full evaluation of the impact on quality of life, the comorbid conditions and if 
appropriate multidisciplinary care has the potential of optimizing long-term patient outcomes.  
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This text offers an overview of the various relevant aspects in the dermatological psoriasis 
assessment, while emphasizing the importance of a holistic approach. In concordance with 
real practice, the structure of a clinical consult is respected throughout this manuscript. The 
demographics of the patient as well as the personal and family history, the drug history, 
current psoriasis-related history and clinical examination are addressed. Finally guidelines are 
provided for further investigations, treatment initiation and follow-up. Gathering this 
information in a preset electronic patient file template (see Tables 1 to 7) has the advantage of 
offering an anchor during consultation. Additionally it has the potential of creating a database 
on which information can be retrieved retrospectively.  
Demographics (Table 1) 
Basic demographic information includes sex, age, ethnicity, skin phototype and family 
planning. Sex and age influence treatment choices and dosage of certain drugs3. Ethnicity has 
an impact on the pharmacokinetics of an individual4 as well as psoriasis prevalence5. 
Employment status and work productivity on the other hand, can be negatively influenced by 
psoriasis and psoriasis arthritis 6,7. Skin phototype offers information about the ability to burn 
or tan when exposed to ultraviolet (UV) radiation, and  is classified using the Fitzpatrick scale 
8
. This needs to be considered in phototherapy risk assessment, where pigmented skin may 
confer more protection against skin cancer9. When recording past UV exposure it is also 
important to find out about UV habits (ea. sunbeds and sunny holidays).  
Asking about the family planning is of importance because hormonal changes in pregnancy 
and post partum influence psoriasis. In the study of Murase et al  55% of the patients reported 
improvement of psoriasis during pregnancy, 21% reported no change and 23% reported 
worsening.10 Furthermore, there are pregnancy-related complications that can be caused by 
both disease and treatment 11. Therefore, the minimum recommended drug-free interval 
before conception is 3 months for men and women taking methotrexate and 2 years for 
women with retinoids12. It is also advised to stop biologic agents in advance, assuring the 
fetus is drug free during the first 12 weeks of critical development. Though, recent data 
suggest that pregnancies in women exposed to TNFα antagonists seem to have similar 
outcomes to those of unexposed pregnancies 13. During the pregnancy itself emollients, 
topical steroids (mild to potent), dithranol and ultraviolet B are safe. Relatively safe are very 
potent topical steroids (in small quantities) and oral cyclosporine. Topical coal tar products 
are not recommended  in the first trimester of the pregnancy because of teratogenicity but are 
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probably safe for use in the second and third trimesters. Prohibited treatments are retinoids , 
calcipotriol derivates, methotrexate and psoralen plus ultraviolet A (PUVA) therapy. Fumaric 
acid esters and biological agents still have unknown effects. In breastfeeding moms 
cyclosporine, retinoids, calcipotriol derivates, methotrexate, PUVA, fumaric acid esters and 
biologic agents should be avoided12. As family planning is a dynamic piece of information 
that may change over time Table 1 needs to be revisited frequently while bearing this in mind.  
Personal and family medical history (Table 2) 
The personal history of the patient should comprise onset of psoriasis, presence of related 
diseases, psychosocial problems and other comorbidities. Additionally, a concise family 
history should be obtained.  
Although possible at any age, a bimodal distribution of age of onset is observed. Type I is the 
early onset type, beginning before or at the age of 40 years, with a peak at the age of 15 to 20 
years. It accounts for more than 75% of the psoriasis patients and disease tends to be more 
severe. Furthermore, more relatives seem to be affected in this type and associations have 
been reported with human leucocyte antigen (HLA)-CW6. Type II psoriasis begins after the 
age of 40 years, mostly occurring at 55 to 60 years 14-16.  
One of the psoriasis related diseases is psoriatic arthritis (PsA), a chronic inflammatory joint 
disease, usually negative for rheumatoid factor. Its prevalence among psoriasis patients is 
about 11% 17, but varies widely 18. Because cutaneous lesions frequently precede joint 
manifestations, dermatologists are uniquely positioned for early detection19. Additionally, 
psoriasis is considered to be one of the immune-mediated inflammatory disorders (IMIDs)20, 
intrinsically having a higher risk for the development of other IMIDs21. Among others, 
associations have been made for psoriasis with inflammatory bowel disease 22,23, multiple 
sclerosis 24,25, uveitis26, lupus erythematosus 27, rheumatoid arthritis27, alopecia areata 28 and 
coeliac disease29.  
Other comorbidities include multiple malignancies30-34 such as non melanoma skin cancer and 
lymphomas. Responsible factors could comprise behavioral risk factors, psoriasis itself and/or 
the psoriasis treatment (e.g. PUVA35,36, cyclosporine 35,37, methotrexate 35,38,39, and some 
biologic therapies35). Metabolic disorders such as hypertension40, insulin resistance 40-44, 
obesity 45-48 and hyperlipidemia49,50 have also been associated with psoriasis. Taken together, 
the metabolic syndrome is far more prevalent compared to the general population 51-54, 
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increasing the risk for type 2 diabetes55 and cardiovascular diseases 56-58. Next to obvious 
behavioral risk factors, it is hypothesized that chronic systemic inflammation in psoriasis 
would be the cause of insulin resistance, leading to endothelial cell dysfunction and 
atherosclerosis 59. In addition, severity of psoriasis seems to be related in a positive dose-
response manner with the severity of complications 53,58,60. As a result, dermatologists should 
take a pro-active role in cardiovascular prevention in this population at risk61, starting 
screening in moderate to severe psoriasis from the age of 20 years 62,63. Further investigations 
regarding surveillance these possible comorbidities will be discussed in detail in a separate 
section later in this text. 
The psychosocial burden of psoriasis affects all facets of a patient's life including 
relationships, social activities, work and emotional wellbeing 64-67. There is an increased risk 
of depression, anxiety, and suicide 68,69, even in pediatric patients 70. Other aspects of 
potential importance in the personal history, especially when giving certain drugs, are serious 
infections (e.g. tuberculosis), liver disease, heart failure, neurologic disease, uncontrolled 
hypertension, renal disease or malignancy 3,71.  
Next to a personal history, family history of psoriasis or related diseases (e.g. IMIDs) should 
be asked for, as psoriasis is a condition that is frequently seen in patients with genetic 
predisposition. It is estimated that the risk for a child to develop psoriasis is one chance on 
four when one parent has psoriasis. If one of two identical twins has psoriasis, there is a 70% 
risk of developing the condition for the other twin72. 
Drug history and vaccination status (Table 3) 
Medical treatments and vaccinations could also be important for future treatment decisions.   
Knowledge of current and past psoriasis medication with their effects and side-effects, is 
important to correctly adjust the treatment of the patient. As PUVA poses a risk of cutaneous 
carcinogenicity, patients’ cumulative exposure to therapeutic UV light should be monitored 
and limited73. Biologic therapy or cyclosporine treatment is relatively contraindicated in 
patients with a high cumulative dose of previous PUVA 3. Non-psoriasis medication gives 
valuable information about the existing comorbidities as well as potential drug interactions3. 
In addition, some treatments can provoke or aggravate psoriasis, such as beta blockers, 
angiotensin-converting enzyme-adrenorecepter inhibitors, gold salts, non-steroidal anti-
inflammatory drugs, anti-malaria medicines, lithium and mepacrine. Exacerbation of psoriasis 
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due to adrenergic antagonists, interferon, gemfibrozil, iodine, digoxin and clonidine has also 
been observed 74. 
The vaccination status is of importance when giving immunosuppressive medication 3,71. 
Administration of the standard vaccinations preferably at least 2 weeks before starting 
therapy, is recommended to ensure optimal immune responses. However, inactivated or 
subunit-based vaccines (e.g. the human papilloma, influenza and pneumococcal vaccine) are 
generally safe and can be considered sufficiently effective during immunosuppression73,75. 
Because of the risk of reactivation, live and live-attenuated vaccines (e.g. varicella, yellow 
fever, and typhoid) should be avoided 75.  
Current history (Table 4) 
The current history offers the dermatologist a good idea of the disease course, while 
correlating this with treatment and environmental influences. Special attention is also 
warranted for the psychosocial impact of the disease.  
 The stability of the skin lesions should be evaluated at every visit, so proper 
adjustments to the therapy can be made. Ask for common triggers for psoriasis such as stress, 
infections, skin trauma, medication and cold weather 76,77. Screening for psoriatic arthritis 
should include asking about joint pain, morning stiffness, swelling, decreased range of motion 
and fatigue78. The interested dermatologist can also use validated screening questionnaires for 
assessment of joint status, e.g. the Toronto Psoriatic Arthritis Screening or the Psoriatic 
Arthritis Screening and Evaluation 79.  
  Environmental influences seem to have a crucial role as trigger for psoriasis. For 
example smoking is linked to psoriasis onset (especially pustular 80,81) 46,82,83 as well as 
clinical severity 84,85. Likewise alcohol consumption is related to the onset 86, severity 87 and 
reduced treatment response88 in psoriasis, with even an increased risk of death 89. A healthy 
diet also positively influences skin lesions90 and response to therapy (e.g. cyclosporine 91). 
Additionally, life style behavior can also influence cardiovascular risk. 
Adequate drug surveillance includes assessing patient adherence to the treatment as well as 
potential side-effects. It can be necessary to ask for symptoms of concurrent infections (e.g. 
tuberculosis), heart failure, neurological disease, liver disease, malignancies or other 
complications92. Dermatologists should verify whether major surgery is foreseen in the future, 
and if so discontinue biologic therapy at least four half-lives prior to the surgery92.  
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  The psychosocial impact of psoriasis plays a substantial role in the perception of 
disease severity, quality of life, and disease course. Nevertheless, this topic remains largely 
unrecognized and undertreated93, as the impact experienced by patients is not always 
proportional to standard measurements of disease severity 94. Simply asking questions about 
depressed mood, anxiety or suicidal intentions could help detecting a need for psychosocial 
help 95. Several health-related quality of life indicators have also been reported, of which the 
dermatology life quality index (DLQI) and the Skindex-29 are the two most commonly used 
outcome parameters in dermatology 96.  
Clinical examination (Table 5) 
Clinical examination should not be limited to skin, nail and joint investigations. Signs related 
to the drug treatment or cardiovascular comorbidity also need to be considered.    
The localization, phenotype and severity of the psoriasis skin lesions must be monitored. 
Chronic plaque psoriasis, inverse psoriasis, guttate psoriasis, erythrodermic psoriasis and 
generalized or palmoplantar pustular psoriasis all have their specific trigger factors and 
prognosis97. However, there is a possible overlap in symptoms and sometimes one type can 
evolve into another throughout a patient’s life. When assessing the clinical disease severity of 
the skin the most commonly used tools are the body surface area (BSA) and the psoriasis area 
and severity index (PASI) 96.  
Coexistent nail involvement is found in up to 55% of the psoriasis patients, and even up to 
90% of the patients with psoriatic arthritis 77. The Nail Psoriasis Severity Index (NAPSI) is a 
reproducible, objective simple scale used to evaluate the severity of nail bed psoriasis and nail 
matrix psoriasis 98. Rheumatologic examination includes screening for psoriatic arthritis when 
complaints of joint problems are present. Redness, swelling and pain, indicating 
characteristics such as enthesopathy, dactylitis and arthritis should be investigated, since early 
treatment interventions can prevent irreversible joint destruction and disability 99-101.  
Drug- related examination implies looking for clues of infection or malignancy, especially 
when taking immunosuppressant therapy. Total body examination comprises exclusion of 
actinic damage, cutaneous malignancies, herpes and viral warts, or managing these conditions 
appropriately. Signs related to liver, neurologic, cardiac or hematological diseases are also of 
relevance 71. Blood pressure measurement and regular weighing can be appropriate e.g. in 
cyclosporine treatment 3.  Implementation of cardiovascular screening for psoriasis patients is 
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only very limited, despite the existence of various guidelines62,63,79,103. At least every 2 years a 
measurement of blood pressure, pulse, body mass index (BMI) and abdominal circumference 
should be done, with referral to a specialist if necessary (see Table 5 for target values) 
62,63,79,102
. 
Further investigations (Table 6)  
Depending on the individual situation, further investigations can include e.g. laboratory 
studies, medical imaging, skin tests and biopsies.  
Rheumatologic investigations such as laboratory studies (e.g. rheumatoid factor) and medical 
imaging (e.g. ultrasonography for swollen joints and radiography for joint malformations) can 
be done by the dermatologist or a rheumatologist in referral, depending on the personal 
expertise. As dermatologists have a primary role in the prevention, screening and follow-up of 
cardiovascular diseases in psoriasis, cardiovascular surveillance became a hot topic 103. 
Several guidelines have been suggested, however with different target values and screening 
intervals 102,104. Summarized, a yearly standard fasting lipid profile and at least 3-yearly 
fasting blood glucose measurement are recommended. C-reactive protein (CRP) or high-
sensitivity CRP should also be determined as they represent the activation of cytokines 
driving inflammation, linking them to atherosclerosis105. CRP assays only report levels > 3 
mg/L. However, the hs-CRP assay reports levels as low as 0.1 mg/L, and is of better use in 
cardiovascular risk stratification. Patients with hs-CRP levels < 1 mg/L are categorized as 
having lower relative risk, while those with levels of 1 to 3 mg/L are at intermediate risk, and 
those with levels > 3 mg/L are at higher relative risk for cardiovascular events.106 Optional 
screening parameters (e.g. hemoglobin A1c, microalbuminuria, lipoprotein-associated 
phospholipase A2 and sex hormone binding globulin 107,108) can be used, but the gains over 
conventional cardiovascular risk factors are minimal109.  
Drug surveillance is warranted to detect associated side-effects. As methotrexate, retinoids 
and cyclosporine represent the first line systemic treatment in Europe for psoriasis 
insufficiently controlled with topical agents or phototherapy, these treatments will be 
discussed in further detail as well as the frequently used biologic therapies.  
Patients on biologicals 71,75,110 need laboratory studies at baseline, month 3 and then every 6 
months with determination of complete blood count, kidney and liver function and pregnancy 
testing. Baseline hepatitis panel and Human Immunodeficiency Virus (HIV) serology can be 
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periodically reassessed in those at risk. Measuring antinuclear antibodies should be limited 
only to situations suspicious for a lupus-like syndrome 75,111. An echocardiogram is 
recommended in patients with NYHA class I and II cardiac failure, as TNF antagonist therapy 
should not be given if the ejection fraction is lower then 50% of the normal. Screening for 
tuberculosis consists of a chest radiograph, purified protein derivative skin test or interferon 
gamma release assay in suspicious cases (suspicion of false positive or false negative 
Mantoux testing). Although not mandatory, annual tuberculosis testing is recommended.  
Baseline evaluations for methotrexate 112-114 include a chest radiograph and blood examination 
with blood count, renal function tests, liver chemistry, procollagen III (PIIINP), pregnancy 
testing, and hepatitis B, C and HIV serology tests if indicated. Folic acid supplementation is 
necessary. In selected cases baseline liver biopsy (e.g. in persistently abnormal PIIINP) and 
tuberculosis screening are considered. Laboratory studies (blood count, liver and renal 
function) should be continued every 2 weeks for 6 weeks after the last dose change, monthly 
thereafter until stabilized and then every 2 to 3 months. In the presence of risk factors or a 
cumulative dose of methotrexate greater than 1.5 g, monitoring of hepatic fibrosis may 
include either measuring PIIINP every 3 to 6 months or performing a Fibroscan and/or 
Fibrotest once a year 114. Hepatologist opinion and liver biopsy are considered in patients with 
chronically elevated PIIINP 114 or every 3.5 to 4.0 g of total cumulative methotrexate dose 112.  
Patients treated with cyclosporine require screening of renal function at baseline, weeks 2, 4, 
6 and 8 and then monthly thereafter 3. Other laboratory investigations should be taken initially 
monthly and thereafter pending the course of therapy. Determination of cyclosporine serum 
concentrations is not part of the routine monitoring. Baseline tuberculosis screening and 
pregnancy testing are recommended. Patients should also attend their dentist at 6-month 
intervals to monitor for gingival hypertrophy 3.  
In acitretin therapy 115 a pregnancy test within 2 weeks prior to therapy is crucial. At baseline 
one should also check the liver function, fasting cholesterol and triglycerides. These 
investigations should be repeated every 2 to 4 weeks for the first 2 months, and then every 3 
months. Other baseline investigations include complete blood count, renal function and 
fasting glucose. Musculoskeletal pain is common and targeted radiographic investigation is 
only recommended if the pain is atypical 114. Children taking acitretin should have their 
growth charted.  
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Skin biopsy is sometimes necessary for histologic confirmation of the diagnosis of psoriasis 
or skin side effects during therapy116. 
Treatment (Table 7) 
Optimal psoriasis management begins with educating the patient, making shared decision 
making possible. The treatment can comprise pharmacotherapy, behavioral modifications and 
multidisciplinary assessments. Clear recommendations should be given concerning the next 
follow-up appointment.   
Education and patient empowerment make it possible for patients to participate in the 
decision-making process, leading to improved adherence117 and better quality of life118. Better 
understanding of the complex relationship with other health issues such as cardiovascular risk, 
may make patients more motivated for behavioural modifications such as a healthy diet, 
physical activity, smoking cessation and cutting down on alcohol consumption. 
Pharmacotherapy includes local or systemic psoriasis treatments and vaccinations (e.g. 
influenza and pneumococcal vaccination during immunosuppressant therapy)71. Additionally 
it can be necessary to deal with comorbidities (e.g. lipid lowering drugs) or side-effects of 
psoriasis therapy (e.g. folic acid supplementation and methotrexate113).  
Referral to a specialist team of interest can be necessary, as management of psoriasis patients 
is shifting towards a more multidisciplinary approach. Regular assessments are advised to 
monitor disease severity, comorbidity, adverse-effects of the treatment, and patient adherence. 
Evaluation of well-controlled localized disease with moderate-strength topical steroids or 
topical retinoids can be done every 6 to 12 months77. Potent topical steroids, systemic 
treatment or complications require more frequent follow-up depending on the individual 
situation.  
Conclusion and discussion 
Psoriasis is a complex multisystem disease, complicated with comorbidities and complex 
treatment options warranting good clinical and biochemical follow-up. Therefore 
dermatologists are in need of a comprehensive practice guidance addressing all relevant 
aspects for a holistic approach to the psoriasis patient. In this manuscript, a template is 
proposed which can be integrated in the currently used electronic patient file, thereby 
minimizing the chances of forgetting certain aspects of psoriasis management. Additionally it 
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gives the potential of retrospectively gathering information out of the electronic system based 
on certain prefixed indexes (ea. gathering all patients with a family history of psoriasis). 
However, to make this consultation proposal practical one might have to reevaluate current 
practice organization. There is a potentially important role for a specifically trained psoriasis 
nurse practitioner in educating, measuring and weighing the patient, as well as taking 
questionnaires and clinical severity scores. The advantage of much of this would be for audit 
and research purposes. If not feasible in the private dermatological practice, one can use an 
adapted “light” version of this exhaustive proposal for the electronic patient file. However, it 
does serve to remind dermatologist and patient of the wider implications of the disease. A 
potential application of this would be for the patient to have a hand held or electronic record 
which could serve as a checklist for the whole team caring for the patient. As a busy 
dermatologist does not always have the time (or sometimes skills) to assess or initiate therapy 
for certain comorbidities, the patient’s general practitioner could assume responsibility for 
assessment of these factors, working as a team.  
Additionally, there is a continuous need for updating and optimizing every aspect of the 
consultation as new evidence and knowledge arise. The example as provided here, should 
therefore not be seen as a static and rigid example for a patient file. It is rather an attempt to 
foresee in a dynamic and adaptable prototype of how to address the individual patient, with 
differing emphasis for one person to the other depending on patient-specific factors.   
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Tables 
 
 Table 1: DEMOGRAPHICS 
Parameter Prefixed choice options Text space 
Age  Specify 
Sex Male  
 Female  
Ethnic group Caucasian  
 Asian  
 African  
 Other Specify 
Phototype I  
 II  
 III  
 IV  
 V  
 VI  
UV habits use of tanning parlors Yes  
  No  
 regular total body sun exposure Yes  
  No  
Employment Active Specify 
 Non-active Specify 
Family planning Current pregnancy Specify 
 
Pregnancy plans Specify 
 
Breast feeding Specify 
Multiple choice boxes can be checked for one parameter. 
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Table 2: PERSONAL AND FAMILY MEDICAL HISTORY 
Parameter Prefixed choice options Text space 
Psoriasis Age start skin lesions  Specify  
 
Evolution Specify 
Psoriatic artritis  Absent   
 
Present Specify treating rheumatologist 
 
Unknown  Specify 
Immune-mediated 
disorders 
Other joint suffering then PsA 
(ea. Rheumatoid arthritis) 
Specify diagnosis and  
 treating rheumatologist  
 
Uveitis Specify 
 
Spondylarthropathy Specify 
 
Inflammatory bowel disease  Specify: Crohn/colitis ulcerosa 
 
Coeliac disease Specify 
 
Vitiligo Specify 
 
Diabetes mellitus type 1 Specify 
 
Multiple sclerosis Specify 
 
Lupus Specify 
 
Alopecia areata Specify 
 
Thyroid disease Specify 
 
Other Specify  
Cardiovascular and 
metabolic disorders Ischemic heart disease Specify 
 
Cerebrovascular accident Specify 
 
Peripheral artery disease Specify 
 
Hypertension Specify 
 
Diabetes mellitus type 2 Specify 
 
Obesity (BMI >30) Specify 
 
Hyperlipidemia Specify 
Malignancies Lymphoma Specify 
 
Non melanoma skin cancer Specify 
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Melanoma skin cancer Specify 
 
Other Specify 
Mental health Depression Specify 
 
Suicidal ideations Specify 
 
Anxiety disorders Specify 
 
Other Specify 
Other personal history Dermatological Specify 
 
Non-dermatological Specify 
 
Allergy Specify 
Family history Psoriasis Specify 
 
Psoriatic artritis Specify 
 
Immune-mediated disorders Specify 
 
Cardiovascular and metabolic 
disorders Specify 
 
Malignancies Specify 
 
Mental health Specify 
 
Other Specify 
 
Table 3: DRUG HISTORY AND VACCINATION STATUS 
Parameter Prefixed choice options Text space  
Vaccination status Pneumococcus Specify date last administration 
 BCG Specify date last administration 
 Influenza Specify date last administration 
 Other Specify vaccine and date of 
administration 
Non-psoriasis medication 
 
Specify 
Past psoriasis treatments Topical  Specify (effect, side-effects, period ) 
 Systemic  Specify (effect, side-effects, period ) 
 UV light therapy  
Specify (effect, side-effects, total 
dose to date, date of last treatment, 
course lenght ) 
Current topical psoriasis Corticosteroids Specify (effect, side-effects, period ) 
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treatment  
 Vitamin D3 Specify (effect, side-effects, period ) 
 Retinoids Specify (effect, side-effects, period ) 
 Tar Products/Dithranol  Specify (effect, side-effects, period ) 
 Other Specify (treatment, effect, side-
effects, period) 
Current systemic psoriasis 
treatment  Methotrexate Specify (effect, side-effects, period ) 
 Cyclosporin Specify (effect, side-effects, period ) 
 Retinoids Specify (effect, side-effects, period ) 
 Corticosteroid Specify (effect, side-effects, period ) 
 Leflunomide Specify (effect, side-effects, period ) 
 Sulfasalazine Specify (effect, side-effects, period ) 
 Infliximab  Specify (effect, side-effects, period ) 
 Etanercept Specify (effect, side-effects, period ) 
 Adalimumab  Specify (effect, side-effects, period ) 
 Ustekinumab Specify (effect, side-effects, period ) 
 Fumaric acid Specify (effect, side-effects, period ) 
 Other Specify (treatment, effect, side-
effects, period) 
Current light therapy PUVA 
Specify (effect, side-effects, total 
dose to date, date of last treatment, 
course lenght ) 
 
Broadband UVB  
Specify (effect, side-effects, total 
dose to date, date of last treatment, 
course lenght ) 
 
Narrowband UVB 
Specify (effect, side-effects, total 
dose to date, date of last treatment, 
course lenght ) 
 
Excimer laser Specify (effect, side-effects, period ) 
BCG: Bacille Calmette Guérin, PUVA: psoralen plus ultraviolet A, UVB: Ultraviolet B 
 
Table 4: CURRENT HISTORY 
Parameter Prefixed choice options Text space  
Disease course 
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Skin lesions Stable Specify 
 Positive evolution Specify 
 Negative evolution Specify 
Current skin symptoms Itch Specify 
 Pain Specify 
 Bleeding Specify 
Triggers Infection Specify 
 Stress  Specify 
 Medication Specify 
 Koebner phenomenon Specify 
 Cold weather Specify 
 Other Specify 
Joint complaints Absent 
 
Peripheral nocturnal pain with 
awakening Specify 
 
 morning stiffness Specify 
 
 swelling 1 or multiple joints Specify 
 
Axial nocturnal pain with 
awakening Specify 
 
 morning stiffness Specify 
 
 swelling 1 or multiple joints Specify 
Behavioral risk factors and lifestyle 
Activity No activity  
 Mild activity  
 Moderate activity (<4x/week during 30 min)  
 Intense activity (>4x/week during 30 min)  
Alcohol No  
 Yes Specify  
Smoking No  
 Yes Specify  
Diet No   
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 Yes  Specify 
Drug surveillance 
Side-effects No  
 Skin problems Specify 
 Non-skin problems  Specify 
Future elective surgery  No 
 Yes Specify 
Adherence No Specify 
 Yes Specify 
Psychosocial impact  
Psychological problems 
Depression Specify 
Anxiety Disorder Specify 
Suicidal ideations Specify 
Dermatological life quality index (DLQI) Specify score 
Skindex-29  Specify score 
 
Table 5: CLINICAL EXAMINATION 
Parameter Prefixed choice options Text space  
Psoriasis phenotype Psoriasis vulgaris Specify if necessary 
 Inverse psoriasis inversa Specify if necessary 
 Guttate psoriasis Specify if necessary 
 Erythrodermic psoriasis Specify if necessary 
 Generalized pustular psoriasis Specify if necessary 
 Pustular psoriasis on palms and soles Specify if necessary 
Localization psoriasis  Hairy scalp Specify if necessary 
 Facial Specify if necessary 
 External auditory Specify if necessary 
 Genital and/or perianal Specify if necessary 
 Hand and feet Specify if necessary 
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 Nails  Specify if necessary 
 Intertriginous areas Specify if necessary 
 Lower limbs Specify if necessary 
 Upper limbs Specify if necessary 
Scores PASI Specify score 
 BSA Specify score 
 NAPSI Specify score 
Joints Absent  
 Dactylitis Specify 
 Enthesitis Specify 
 Arthtitis Specify 
Drug- related examination Viral skin infections Specify 
 Skin (pre)canceroses Specify 
 Signs of infection Specify 
 Signs of malignancy Specify 
 Other Specify 
Tension (mmHg)  
(target value: < 140-120 mmHg systolic and < 90-80 mmHg diastolic) Specify 
Pulse (pm) 
 
Specify 
Length (m) 
 
Specify 
Weight (kg) 
 
Specify 
BMI  
(target value: < 25kg/m2)  Calculated  
Abdominal circumference 
(target value: < 102 cm in male and  < 88 cm in women) Specify 
Additional remarks 
 
Specify 
PASI: Psoriasis Area and Severity Index, BSA: Body Surface Area, NAPSI: NailPsoriasis Severity 
Index, BMI: Body Mass Index  
 
Table 6: FURTHER INVESTIGATIONS 
Parameter Prefixed choice options Text space  
Cardiovascular 
profile 
Fasting lipid profile 
(target values: total cholesterol < 200 mg/dL,  Specify 
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high-density lipoprotein cholesterol ≥ 50 mg/dL,  
low-density lipoprotein cholesterol < 100 mg/dL) 
 
Fasting blood glucose 
(target value: < 100 mm/dL) Specify 
 CRP Specify 
Drug surveillance Acitretin  
  Liver function Specify 
  
Fasting serum cholesterol and 
triglycerides Specify 
  Renal function Specify 
  Fasting glucose Specify 
  Sedimentation Specify 
  Creatin kinase Specify 
  Pregnancy test Specify 
  Radiological investigations Specify 
 Methotrexate 
  Complete blood cell and platelet count Specify 
  Renal function Specify 
  Liver function  Specify 
  Procollagen III Specify 
  Hepatitis B and C and HIV serology Specify 
  Pregnancy test Specify 
  Chest radiograph Specify 
  Tuberculosis screening Specify 
  Liver biopsy Specify 
 Cyclosporine  
  Complete blood cell and platelet count Specify 
  Renal function Specify 
  Glomerular filtration rate Specify 
  Uric acid Specify 
  Magnesium and potassium Specify 
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  Liver function Specify 
  Fasting lipid profile Specify 
  Pregnancy test Specify 
  Urinalysis Specify 
  Tuberculosis screening Specify 
  Dental screening Specify 
 Biological  
  Complete blood cell and platelet count  Specify 
  Renal function Specify 
  Liver function  Specify 
  Hepatitis B and C and HIV serology Specify 
  Anti-nuclear antibodies Specify 
  Anti-drug antibodies Specify 
  Pregnancy test Specify 
  Urine analysis Specify 
  Chest radiograph Specify 
  Tuberculosis screening Specify 
  Echocardiogram Specify 
 Other Specify 
Biopsy No 
 Yes Protocol 
CRP: C-reactive proteine 
 
Table 7: INITIATED TREATMENT 
Parameter Prefixed choice options Text space  
Topical treatment  
Corticosteroids Specify (period and frequency) 
Vitamin D3 Specify (period and frequency) 
Retinoids Specify (period and frequency) 
 Tar Products/Dithranol  Specify (period and frequency) 
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 Other Specify (treatment, period and frequency) 
Systemic psoriasis 
treatment  Retinoids  Specify (period and frequency) 
 Methotrexate and folic acid Specify (period and frequency) 
 Cyclosporin Specify (period and frequency) 
 Corticosteroid Specify (period and frequency) 
 Infliximab  Specify (period and frequency) 
 Etanercept Specify (period and frequency) 
 Adalimumab  Specify (period and frequency) 
 Ustekinumab Specify (period and frequency) 
 Other Specify( treatment, period and frequency) 
Light therapy PUVA Specify (period and frequency) 
 UVB Specify (period and frequency) 
 Excimer laser Specify (period and frequency) 
New vaccinations   
Other    
Information and advise Specify lifestyle advise 
Referral No  
 Yes Specify reason and advice 
Next appointment   Specify follow-up interval 
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Chapter 6: General conclusions and future perspectives  
The present thesis intended to gain more insight in improving the quality of care for psoriasis 
patients. Therefore, three aims were formulated in Chapter 2.  
In this chapter, a summary of the major conclusions and future perspectives of the presented 
articles will be given and discussed. In addition, we will discuss what we learned from this 
thesis and what could be improved. Lastly, clinical implications of this thesis will be given. 
Aim 1: To acquire new insights in the complex association between psoriasis, 
psoriatic arthritis and metabolic syndrome (Chapter 3) 
We performed a cross-sectional study in 123 patients with psoriasis of the skin (PsO) and 
psoriasis arthritis (PsA). We found that prevalence of the metabolic syndrome according to 
the criteria of the International Diabetes Foundation was significantly higher in the PsO 
(44,9%) compared to the PsA group (25,5%) (p=0,037). Looking closer at the individual 
components of the metabolic syndrome, this difference can mainly be attributed to the 
significantly higher prevalence of abdominal obesity in PsO (83,7%) versus PsA (65,5%) (p= 
0,034). This association was even enhanced after multivariate adjustments for confounding 
factors such as age, disease severity, disease duration, systemic therapy and systemic 
inflammation.  These findings suggest that screening for metabolic syndrome should be 
considered especially in the group of PsO patients. Furthermore, we suspect an 
undertreatment of the cardiovascular risk factors in our study population. Managing 
cardiovascular risk by initiating preventive cardiovascular pharmacotherapy and life style 
modifications is essential in these patients.    
In future studies, the causality of the association between PsO, PsA and metabolic syndrome 
should be further elucidated. Long-term data should be acquired on the impact of earlier 
intervention with systemic therapies in psoriasis. In particular, the effect of biologics on 
cardiovascular and metabolic comorbidities should be elucidated. This may have important 
implications for the choice of treatment.   
Furthermore, future prospective studies should aim at validating biomarkers differentiating 
PsA from patients with PsO. This enables early detection of PsA in PsO patients. In addition, 
it allows differentiating  PsO from PsA for future research.  
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Aim 2: To evaluate the added value of the Ghent University educational 
programme (Chapter 4) 
We conducted a randomized controlled trial (RCT) in adult patients with psoriasis and atopic 
dermatitis to evaluate the added value of our 12 week educational programme consisting of 
education about skin diseases and life style factors and stress-reduction techniques. We found 
two major conclusions of  this study: Firstly, in our RCT we found an improvement in disease 
severity, quality of life and depression status after the educational programme for psoriasis 
patients but not for atopic dermatitis patients. Psoriasis patients in the intervention group 
showed a significant reduction in mean PASI (p=0.036), mean Dermatology Life Quality 
Index (p=0.019), mean Psoriasis Disability Index (p=0.015) and mean Beck Depression 
Inventory (p=0.029), compared with the control group after the programme.  Similar to this, 
we found that in general there is more evidence according to literature for the effectiveness of 
the different components of the educational programme for psoriasis compared to atopic 
dermatitis. (Table 1)  
Table 1: Evidence for different components of the educational programme in patients with psoriasis 
and atopic dermatitis according to literature. 
 Psoriasis Atopic dermatitis 
1. Specific information on skin disease    
a. Information session on skin disease  a2-4 a3,5,6 
b. Skin care  a2-4 a3,5,6 
2. Stress-reduction techniques   
a. Physical training           a7                 c 
b. Yoga           c                 c 
c. Mindfulness-based stress reduction           b8                 c 
3. Information sessions on life style    
a. Diet           a9                 c 
b. Responsible physical training           a7                 c 
c. Sleep hygiene  b10                 a6,11 
d. Smoking cessation     a12,13                 b14 
e. Substance abuse  a15                 c 
f.  Psycho-dermatology     a16,17                 b18 
g. Practical philosophy           c                 c 
4. Feedback   
a. Individual dermatologist           ?                 ? 
b. In group          ?                 ? 
a = strong evidence; b = preliminary results; c = no evidence 
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Secondly, the improved outcomes for psoriasis patients after the programme continued for at 
least 3 months after the intervention, but seems to wane after 6 months after the intervention. 
Therefore, we can conclude that it would be interesting to offer the components of the 
programme on a more continuous basis.  
In our RCT we found that the positive effect of intensive physical activity in the intervention 
group waned after 9 months follow-up. Hereby, we can conclude that moderate physical 
activity incorporated in the daily lives of the patients would be a better alternative to maintain 
these positive effects. This hypothesis should be validated in future studies.  
Additional to this, it would be interesting to study the effects of the individual elements of the 
programme in psoriasis patients. The impact of different stress-reducing techniques and their 
biological effects on brain and immune function can be an important research topic. Also, the 
educational part of the programme and its effect on patient outcomes and adherence to 
therapy should be examined separately. 
Furthermore, determination of the external validity of the programme is an important issue. 
The review of De Bes et al summarises evidence concerning the effects of patient education in 
patients with chronic skin diseases.19 They found a moderate external validity in 9 of the 10 
RCT’s and only 1 had a sufficient external validity. The most important factor that interferes 
with the generalisability of our educational programme is the resource intensity of the 
programme. Therefore, we might suggest to organise the educational part of the programme 
by the centre itself and to work in collaboration with existing centres for sports, yoga and 
mindfulness. In this context, it is important to agree on a common setting for groups of 
patients with skin diseases with these centres.  
Aim 3: To give an overview of updated relevant aspects in the clinical 
dermatological assessment of psoriasis patients (Chapter 5) 
In this review paper we give a structured summary of relevant aspects in the clinical 
assessment of psoriasis patients anno 2012. At first, relevant aspects about patient’s 
demographics, personal and family medical history, drug history and vaccination status are 
discussed. Secondly, clinical examination to assess disease severity and impact on quality of 
life is reviewed. Special attention is given in the first two items to detect comorbidities and 
adverse effects of therapy. Thirdly, further investigations are discussed with emphasis on 
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good pre-treatment screening and therapy follow-up. Lastly, emphasis is given on patient 
education that makes shared decision making possible and a multidisciplinary approach in the 
management of psoriasis. 
Based on this information, a template is proposed which can be integrated in the currently 
used electronic patient file. Hereby, we want to give an anchor during consultation and create 
the potential of gathering information for future research.  
What have we learned? What could be improved? 
The design of this thesis is oriented to the clinical question: “What can be improved in the 
care for psoriasis patients?”. Therefore, it is of practical use for the clinician treating psoriasis 
patients. As many different subfields are included, the knowledge of these different areas is 
difficult to maintain. 
Overall, we learned that a good selection of the measurement methods will help to reduce 
labour-intensiveness of the studies. For this and for the preparation of the design of the study, 
enough time and experience is needed. Concerning measurement methods, an important part 
of the process for developing an effective educational intervention is measuring self-efficacy 
levels. Self-efficacy has been shown to be one of the most consistent predictors of successful 
self-care behaviour and should therefore be incorporated in future studies on educational 
programmes.20 Also, an accurate sample size calculation in advance can prevent difficulties in 
the progress of the study. Next to this, we noticed that the recruitment of the patients takes a 
lot of effort, this should not be underestimated in time and labour-intensiveness.  
In particular for the RCT about our educational programme, we encountered some difficulties 
in conducting a pragmatic randomised controlled trial. First of all, randomisation of the 
patients caused sometimes disappointment when ending up in the control group. Along the 
way, the patients were better prepared to this randomisation and the disappointment was not 
as large. Also blinding of the assessors was not an easy task. Patients were told not to mention 
in which group they were randomised to the assessors but sometimes revealed something 
about the programme.  
In addition, in the reporting of the feasibility study on the Ghent University educational 
programme (paper 2), we jumped to conclusions too soon. This concerns the following part 
on page 59 “Furthermore, validated questionnaires revealed that the health related quality of 
life significantly improved after the intervention. Specifically, women with atopic dermatitis 
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(n=9) seemed to benefit most from the programme with regard to quality of life.” These 
conclusions are surpassed by the results of our RCT which shows effectiveness in psoriasis 
patients but not in atopic dermatitis patients.  
Unfortunately, we could not show cost-effectiveness of the programme at 6 months. The EQ-
5D questionnaire was used to calculate quality adjusted life years needed to measure cost-
utility of the programme. Our first problem was that EQ-5D values in intervention group were 
not significantly better than in the control group. For future studies in dermatology, 
dermatology life quality index (DLQI) should be a better questionnaire to calculate quality 
adjusted life years and ultimately cost-utility of an intervention.21 Next to this, we did not see 
any difference in medical consumption nor absenteeism between the groups. Therefore, the 
cost programme per patient could not be lowered by gain in medical resource spending or 
taking into account absenteeism. In addition, a larger sample size and a longer follow-up 
period are needed to draw conclusions with regard to cost-effectiveness of the programme.  
In the future it could be of help to take this comments into account when setting up and 
conducting similar studies. 
Clinical implications 
The results of this thesis show the importance of screening for metabolic and cardiovascular 
disease, especially in patients with psoriasis of the skin. Besides, previous research showed 
that early detection of other comorbidities such as psoriatic arthritis is essential to improve 
outcomes in psoriasis.22 This can be achieved by increasing awareness among physicians 
treating psoriasis patients and establishing appropriate screening methods. In addition, 
psoriasis patients should be supported in lifestyle modifications if indicated such as weight 
loss, physical activity, stress-reduction, smoking cessation and tackling alcohol abuse. 
Therefore, organising sports for groups of patients with psoriasis or in general, skin diseases, 
can be of help. Also, patients at increased risk at developing psoriasis, such as a familial 
affliction, should be encouraged to maintain a healthy lifestyle (regular physical activity, 
healthy diet, participation to stress-reduction exercises, smoking cessation and alcohol 
limitation). Furthermore, patient education improves health outcomes and adherence to 
therapy and should therefore be integrated in the management of psoriasis.  
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Summary 
Psoriasis is a common chronic inflammatory disease affecting approximately 2% of the 
population in Europe and the United States and is less prevalent elsewhere. Although 
traditionally psoriasis has been considered a dermatologic disease, it is being recognized that 
psoriasis is associated with other comorbidities. They may arise from a genetic predisposition, 
from the side effects of antipsoriatic treatments, from the lifestyles of psoriatic patients or 
more recently being hypothesized, from the chronic inflammatory nature of psoriasis. The 
comorbidities in psoriasis may be linked by common inflammatory pathways involving 
cytokine dysregulation or share a genetic basis. In addition, conditions linked with psoriasis 
have been associated with increasing rates of considerable morbidity and mortality. 
Furthermore, psoriasis has a significant physical, social, and psychological burden. This  
major impact on patient’s quality of life can lead to disruption of daily activities, social 
relationships and negative self-image.  Also, lifestyle factors such as physical inactivity, 
smoking, alcohol consumption, obesity and stress are of greater importance because of their 
negative influence on psoriasis and its comorbidities. 
In Chapter 1 we look closer at psoriasis anno 2012. The comorbidities associated with 
psoriasis are discussed. In addition, we discuss the health-related quality of life of  psoriasis 
patients and the lifestyle factors which have an influence on the onset and course of psoriasis. 
Next to this, we elaborate on the problem of adherence to therapy in psoriasis patients and 
what can be changed to improve this. 
Most common comorbidity in psoriasis is inflammatory arthritis. Psoriatic arthritis usually 
follows skin manifestations but in approximately 15% it may precede them. The correlation of 
skin and joint symptoms in patients with psoriasis and psoriatic arthritis can vary 
considerably. In Chapter 3 we discuss the similarities and differences between psoriasis and 
psoriatic arthritis with respect to epidemiology, genetics and immunology. Furthermore, we 
present our first paper on the association of metabolic syndrome in psoriasis versus psoriasis 
arthritis.  
The presence of comorbid conditions in psoriasis patients has important implications for 
clinical management. The principal aim of  therapy is to reduce the burden of the disease over 
time by controlling symptoms, helping patient to cope with the chronic nature of the disease, 
reducing psychologic and relational burden and preventing systemic complications and 
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comorbidities. Therefore, psychological support and support for lifestyle modifications  
should be given next to optimal medical care. Also, screening for comorbidities is important 
that makes essential referral possible. Besides, efficiently informing patients through 
education and improving adherence to therapy may complement standard care. In this context, 
we present our educational programme for chronic skin diseases in paper 2 and our 
randomized, controlled trial for psoriasis and atopic dermatitis patients in paper 3. (Chapter 4)  
Lastly, in our fourth paper we give a summary of updated relevant aspects in the clinical 
dermatological assessment of psoriasis patients, emphasizing the importance of a 
multidisciplinary and holistic clinical approach. (Chapter 5) 
In conclusion, with this approach we hope to improve the quality of care for psoriasis patients  
and ultimately the long-term quality of life in the psoriasis population. 
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Samenvatting 
Psoriasis is een veelvoorkomende, chronische inflammatoire aandoening met een prevalentie 
van ongeveer 2% in Europa en de Verenigde Staten en komt minder voor elders. Alhoewel 
traditioneel psoriasis wordt beschouwd als een dermatologische aandoening, wordt het erkend 
dat psoriasis geassocieerd is met meerdere comorbiditeiten. Deze kunnen ontstaan vanuit een 
genetische voorbeschiktheid, door bijwerkingen van psoriasis behandelingen, door de 
levensstijl van de psoriasis patiënten of meer recent geopperd, door de chronische 
inflammatoire aard van psoriasis. De comorbiditeiten in psoriasis kunnen gemeenschappelijke 
inflammatoire pathways hebben waarbij cytokine dysregulatie een belangrijke rol speelt of 
kunnen een genetische basis delen. Daarnaast zijn deze comorbiditeiten in psoriasis 
geassocieerd met een aanzienlijke morbiditeit en mortaliteit. 
Bovendien zorgt psoriasis voor een aanzienlijke fysieke, sociale and psychologische 
belasting. Deze grote impact op de kwaliteit van leven van de patiënt kan leiden tot verstoring 
van de dagelijkse activiteiten en sociale relaties en het creëren van een negatief zelfbeeld.  
Daarnaast zijn ook de levensstijl factoren zoals fysieke activiteit, roken, alcohol misbruik, 
obesiteit en stress van groot belang omwille van hun negatieve invloed op psoriasis en de 
comorbiditeiten. 
In hoofdstuk 1 gaan we dieper in op psoriasis anno 2012. De comorbiditeiten geassocieerd 
met psoriasis worden besproken. We bespreken de invloed van psoriasis op de kwaliteit van 
leven en de levensstijl factoren die een invloed hebben op het ontstaan en het verloop van 
psoriasis. Daarnaast, gaan we ook dieper in op het probleem van therapietrouw bij psoriasis 
patiënten en wat er kan veranderd worden om dit te verbeteren.  
De meest voorkomende comorbiditeit in psoriasis is een inflammatoire arthritis. Psoriasis 
arthritis ontstaat meestal nadat de huidsymptomen reeds aanwezig zijn alhoewel in ongeveer 
15% kan het de huidsymptomen voorafgaan. Het verband tussen huid- en 
gewrichtssymptomen in patiënten met psoriasis en psoriasis arthritis is onduidelijk. In 
hoofdstuk 3 bespreken we de gelijkenissen en de verschillen tussen psoriasis en psoriasis 
arthritis op vlak van epidemiologie, genetica en immunologie. Daarnaast, presenteren we ons 
eerste artikel over de associatie van het metabool syndroom in psoriasis versus psoriasis 
arthritis.   
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Het voorkomen van comorbiditeiten in psoriasis heeft belangrijke implicaties voor de 
klinische aanpak. Het voornaamste doel van de therapie is om de belasting van de ziekte te 
verminderen na verloop van tijd door beheersing van de symptomen, patiënten te helpen beter 
om te gaan met de chroniciteit van de aandoening, het verminderen van psychologische en 
relationele belasting and het voorkomen van systemische complicaties en comorbiditeiten. 
Daarvoor zijn naast optimale medische zorg ook psychologische ondersteuning en 
ondersteuning voor levensstijl veranderingen noodzakelijk. Daarnaast is het belangrijk om te 
screenen voor comorbiditeiten in psoriasis wat verwijzing naar een specialist ter zake 
mogelijk maakt. Bovendien is het efficiënt informeren van de patiënten door educatie en 
hiermee het verbeteren van de therapietrouw een belangrijke aanvulling op de standaard zorg. 
In deze context, presenteren we ons educationeel programma voor patiënten met chronische 
huidziekten in artikel 2 en onze gerandomiseerde, gecontroleerde studie voor psoriasis en 
atopisch eczeem patiënten in artikel 3. (Hoofdstuk 4)  
Als laatste geven we een samenvatting van de relevante aspecten in de klinische 
dermatologische beoordeling van psoriasis patiënten in ons vierde artikel. Hierbij ligt de 
nadruk op het belang van een multidisciplinaire en holistische klinische benadering. 
(Hoofdstuk 5) 
Kortom, hopen we met deze aanpak de kwaliteit van zorg voor psoriasis patiënten en 
uiteindelijk de kwaliteit van leven in de psoriasis populatie op lange termijn te verbeteren. 
 Summary – Samenvatting – Résumé 
 
 
137 
 
Résumé 
Le psoriasis est une affection inflammatoire chronique courante, avec une prévalence 
d'environ 2% en Europe et aux Etats-Unis. La maladie est moins répandue ailleurs. Bien que, 
traditionnellement, le psoriasis soit considéré comme affection dermatologique, il est admis 
qu'il est associé avec plusieurs comorbidités. Celles-ci peuvent être issus d'une prédisposition 
génétique, des effets secondaires du traitement du psoriasis, du mode de vie des patients, ou, 
comme suggéré récemment, du caractère inflammatoire de la maladie. Les comorbidités du 
psoriasis peuvent avoir des filières inflammatoires communes, ou partager une même base 
génétique. Par ailleurs, ces comorbidités du psoriasis sont associés à une morbidité et 
mortalité considérables. 
Le psoriasis représente une charge physique, psychologique et sociale importante. Cet impact 
sur la qualité de vie du patient peut provoquer des perturbations dans les activités 
quotidiennes, les relations sociales et créer une image de soi négative. 
Par ailleurs, les facteurs liés au mode de vie, tels que sédentarité, tabagisme, abus d'alcool, 
obésité ou stress sont encore plus importants de par l'effet négatif sur le psoriasis et ses 
comorbidités. 
Dans le premier chapitre on approfondira le psoriasis anno 2012. Nous discuterons les 
comorbidités associés avec le psoriasis. De plus nous étudierons la qualité de vie des patients 
psoriasiques et nous parlerons des facteurs du mode de vie qui influencent l'origine et le cours 
de la maladie. De plus nous considèrerons le suivi thérapeutique par le patient et les facteurs 
qui peuvent être améliorés. 
La comorbidité la plus courante du psoriasis est une arthrite inflammatoire. L'arthrite 
psoriasique apparaît en général après les symptômes cutanés; mais dans 15% des cas elle les 
précèdent. La corrélation entre symptômes cutanés et articulaires chez le patient psoriasique 
atteint d'arthrite psoriasique est très variable. Dans le troisième chapitre nous considèrerons 
les similitudes et les différences entre le psoriasis et l'arthrite psoriasique sur le plan 
épidémiologique, génétique et immunologique. De plus nous présenterons notre troisième 
article sur l'association du syndrome métabolique dans le psoriasis versus l'arthrite 
psoriasique. 
La présence de comorbidités chez le patient psoriasique a des implications importantes sur la 
prise en charge clinique. L'objectif principal du traitement est la diminution du fardeau de la 
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maladie au fil du temps, en maîtrisant les symptômes, en aidant les patients à mieux prendre 
en charge la chronicité de leur maladie, en diminuant la charge psychologique et relationnelle 
et en assurant la prévention des complications systémiques et des comorbidités.  
Pour cela, à côté de l'optimalisation des soins médicaux, il est nécessaire d'assurer le soutient 
psychologique et le suivi des modifications du mode de vie. De plus, il est important de 
détecter les comorbidités dans le psoriasis, afin d'assurer le renvoi du patient vers le 
spécialiste compétent. Enfin, il est important de compléter les soins de base par une éducation 
du patient par une information efficace, et ainsi améliorer le suivi thérapeutique par le patient. 
Dans ce contexte, nous présenterons notre programme éducatif du patient atteint d'une 
maladie chronique de la peau dans le deuxième article, et notre étude contrôlée et randomisée 
concernant le psoriasis et les patients atteint d'eczéma atopique dans le troisième article 
(chapitre 4). 
Pour finir, nous donnerons un aperçu des aspects pertinents de l'évaluation dermatologique 
clinique du patient psoriasique dans notre quatrième article. Nous mettrons l'accent sur 
l'importance d'une approche clinique multidisciplinaire et holistique (chapitre 5). 
Nous espérons améliorer de cette façon, à long terme, la qualité des soins et la qualité de vie 
de tous les patients atteint par le psoriasis. 
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